Caution: Federal Law restricts this device to sale by or on the order of a physician or licensed practitioner.

Size: px
Start display at page:

Download "Caution: Federal Law restricts this device to sale by or on the order of a physician or licensed practitioner."

Transcription

1 Restylae Lyft with Lidocaie Ijectable Gel with.3% Lidocaie Cautio: Federal Law restricts this device to sale by or o the order of a physicia or licesed practitioer. Descriptio Restylae Lyft with Lidocaie is a sterile gel of hyaluroic acid geerated by Streptococcus species of bacteria, chemically cross-liked with BDDE, stabilized ad suspeded i phosphate buffered salie at ph=7 ad cocetratio of mg/ml with.3% lidocaie. Idicatio Restylae Lyft with Lidocaie is idicated for implatatio ito the deep dermis to superficial subcutis for the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds. Restylae Lyft with Lidocaie is idicated for subcutaeous to supraperiosteal implatatio for cheek augmetatio ad correctio of age-related midface cotour deficiecies i patiets over the age of. Restylae Lyft with Lidocaie is idicated for ijectio ito the subcutaeous plae i the dorsal had to correct volume deficit i patiets over the age of. Cotraidicatios Restylae Lyft with Lidocaie is cotraidicated for patiets with severe allergies maifested by a history of aaphylaxis or history or presece of multiple severe allergies. Restylae Lyft with Lidocaie cotais trace amouts of gram positive bacterial proteis, ad is cotraidicated for patiets with a history of allergies to such material. Restylae Lyft with Lidocaie is cotraidicated for patiets with bleedig disorders. Warigs Restylae Lyft with Lidocaie should ot be used i patiets with previous hypersesitivity to local aesthetics of the amide type, such as lidocaie. Itroductio of Restylae Lyft with Lidocaie ito the vasculature may lead to embolizatio, occlusio of the vessels, ischemia, or ifarctio. Take extra care whe ijectig soft tissue fillers, for example iject the product slowly ad apply the least amout of pressure ecessary. Rare but serious adverse evets associated with the itravascular ijectio of soft tissue fillers i the face have bee reported ad iclude temporary or permaet visio impairmet, blidess, cerebral ischemia or cerebral hemorrhage, leadig to stroke, ski ecrosis, ad damage to uderlyig facial structures. Immediately stop the ijectio if a patiet exhibits ay of the followig symptoms, icludig chages i visio, sigs of a stroke, blachig of the ski or uusual pai durig or shortly after the procedure. (49)

2 Patiets should receive prompt medical attetio ad possibly evaluatio by a appropriate health care practitioer specialist should a itravascular ijectio occur. Defer use of Restylae Lyft with Lidocaie at specific sites i which a active iflammatory process (ski eruptios such as cysts, pimples, rashes, or hives) or ifectio is preset util the process has bee cotrolled. Ijectio site reactios (e.g., swellig, redess, tederess, or pai) to Restylae Lyft with Lidocaie have bee observed as cosistig maily of short-term mior or moderate iflammatory symptoms startig early after treatmet ad with less tha weeks duratio. Refer to the adverse reactios sectio for details. As with all dermal filler procedures, Restylae Lyft with Lidocaie should ot be used i vascular rich areas. Use i these highly vascularized areas, such as glabella ad ose, has resulted i cases of vascular embolizatio ad symptoms cosistet with ocular vessel occlusio, such as blidess, ad with brai vessel occlusio resultig i cerebral ifarctio. Delayed oset iflammatory papules have bee reported followig the use of dermal fillers. Iflammatory papules that may occur rarely should be cosidered ad treated as a soft tissue ifectio. Special care should be take to avoid ijectio ito veis or tedos i the had. Ijectio ito tedos may weake tedos ad cause tedo rupture. Ijectio ito veis may cause embolizatio or thrombosis. Ijectio ito the had may cause adverse evets that last for more tha 96 days. I a cliical study, 4.7% of subjects had at least a degree egative chage i thumb flexio which persisted through the course of the 6-moths duratio study. Refer to adverse evets sectios for additioal details. Ijectio of the dorsum of the had may cause pai i extremity ad peripheral swellig. Ijectio of Restylae Lyft i the had ad post-treatmet behavior such as streuous use or trauma to the hads may icrease the risk for delayed oset AEs i the had. Precautios Restylae Lyft with Lidocaie is packaged for sigle patiet use. Do ot resterilize. Do ot use if package is opeed or damaged. For the treatmet of moderate to severe facial wrikles ad folds, the maximum recommeded dose per treatmet is 6. ml based o U.S. cliical studies. For cheek augmetatio implatatio ad the treatmet of age-related midface volume deficit i patiets over the age of the maximum recommeded dose is also 6. ml per treatmet. For the treatmet of dorsal had volume deficit, the maximum recommeded dose per had is 3. ml based o U.S. cliical studies. The safety of ijectio greater amouts has ot bee established. (49)

3 The safety or effectiveess of Restylae Lyft with Lidocaie for the treatmet of aatomic regios other tha asolabial folds, midface area ad dorsal had has ot bee established i cotrolled cliical studies. Log term safety ad effectiveess of Restylae Lyft with Lidocaie beyod oe year have ot bee ivestigated i cliical trials. As with all trascutaeous procedures, Restylae Lyft with Lidocaie implatatio carries a risk of ifectio. Stadard precautios associated with ijectable materials should be followed. The safety ad efficacy of Restylae Lyft with Lidocaie for lip augmetatio has ot bee established. The safety of Restylae Lyft with Lidocaie for use durig pregacy, i breastfeedig females or i patiets uder 8 years has ot bee established. Formatio of keloids may occur after dermal filler ijectios icludig Restylae Lyft with Lidocaie. Keloid formatio was ot observed i studies ivolvig 79 patiets (icludig 6 Africa-Americas ad 76 other patiets of Fitzpatrick Ski Types IV, V ad VI). For additioal iformatio please refer to Studies MA-4-, MA-4-, 3GE, 3GE, ad MA-4-5 i the Cliical Trials Sectio. I study MA-4-3 with Restylae Lyft with Lidocaie ad Perlae, there were 5.7% (3/6) of patiets with Fitzpatrick Ski Types IV, V, ad VI ad o reports of keloid formatio. Restylae Lyft with Lidocaie ijectio may cause hyperpigmetatio at the ijectio site. I a cliical study of 5 patiets with pigmeted ski (of Africa-America heritage ad Fitzpatrick Ski Types IV, V, ad VI), the icidece of post-iflammatory hyperpigmetatio was 6% (9/5). 5% of these evets lasted up to six weeks after iitial implatatio. I study MA-4-3 with Perlae ad Restylae Lyft with Lidocaie, there were 5.7% (3/6) of patiets with Fitzpatrick Ski Types IV, V, ad VI ad o reports of hyperpigmetatio. I study MA-4-5 with Restylae Lyft with Lidocaie, there were 3.5% (6/) of patiets with Fitzpatrick Ski Types IV, V, ad VI ad o reports of hyperpigmetatio. Restylae Lyft with Lidocaie should be used with cautio i patiets o immuosuppressive therapy. Use of Restylae Lyft with Lidocaie i dorsal had i patiets with diseases, ijuries or disabilities of the had has ot bee studied. Care should be used i treatig patiets with autoimmue disease affectig the had, had implats, Dupuytre s cotracture, history of had tumor, vascular malformatios, Rayaud s disease ad patiets at risk for tedo rupture. Bruisig or bleedig may occur at Restylae Lyft with Lidocaie ijectio sites. Restylae Lyft with Lidocaie should be used with cautio i patiets who have udergoe therapy with thrombolytics, aticoagulats, or ihibitors of platelet aggregatio i the precedig 3 weeks. After use, syriges ad eedles should be hadled as potetial biohazards. Disposal should be i accordace with accepted medical practice ad applicable local, state, ad federal requiremets. 3 (49)

4 The safety of Restylae Lyft with Lidocaie with cocomitat dermal therapies such as epilatio, UV irradiatio, or laser, mechaical or chemical peelig procedures has ot bee evaluated i cotrolled cliical trials. Patiets should miimize exposure of the treated area to excessive su, UV lamp exposure ad extreme cold weather at least util ay iitial swellig ad redess has resolved. If laser treatmet, chemical peelig or ay other procedure based o active dermal respose is cosidered after treatmet with Restylae Lyft with Lidocaie, there is a possible risk of elicitig a iflammatory reactio at the implat site. This also applies if Restylae Lyft with Lidocaie is admiistered before the ski has healed completely after such a procedure. Ijectio of Restylae Lyft with Lidocaie ito patiets with a history of previous herpetic eruptio may be associated with reactivatio of the herpes. Restylae Lyft with Lidocaie is a clear, colorless gel without particulates. I the evet that the cotet of a syrige shows sigs of separatio ad/or appears cloudy, do ot use the syrige ad otify Galderma Laboratories, L.P. at Glass is also subject to breakage uder a variety of uavoidable coditios. Care should be take with the hadlig of the glass syrige ad with disposig of broke glass to avoid laceratio or other ijury. Restylae Lyft with Lidocaie should ot be mixed with other products before implatatio of the device. Cheek augmetatio or correctio of age-related midface cotour deficiecies i patiets over the age of,with Restylae Lyft with Lidocaie should oly be performed by physicias who have appropriate experiece ad who are kowledgeable about the aatomy ad the product for use i deep (subcutaeous ad/or supraperiosteal) ijectio for cheek augmetatio. Correctio of volume deficit i the dorsal had i patiets over the age of, with Restylae Lyft with Lidocaie should oly be performed by physicias who have appropriate experiece ad who are kowledgeable about the aatomy ad the product for use i the subcutaeous plae. Safety of Restylae Lyft with Lidocaie ijected ito the dorsum of the had i patiets uder years old has ot bee studied. I order to miimize the risks of potetial complicatios, this product should oly be used by health care practitioers who have appropriate traiig, experiece, ad who are kowledgeable about the aatomy at ad aroud the site of ijectio. Health care practitioers are ecouraged to discuss all potetial risks of soft tissue ijectio with their patiets prior to treatmet ad esure that patiets are aware of sigs ad symptoms of potetial complicatios. Adverse Experieces Restylae Lyft with Lidocaie is idicated for implatatio ito the deep dermis to superficial subcutis for the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds ad for subcutaeous to supraperiosteal implatatio for cheek augmetatio ad correctio of agerelated midface cotour deficiecies i patiets over the age of. It is also idicated for ijectio ito the subcutaeous plae i the dorsal had to correct volume deficit i patiets over the age of. Adverse evet iformatio for Restylae Lyft with Lidocaie use i the correctio of moderate 4 (49)

5 to severe facial folds ad wrikles, such as asolabial folds is preseted i Tables - ad for cheek augmetatio ad correctio of age-related midface cotour deficiecies is preseted i Tables -3. Adverse evet iformatio for Restylae Lyft with Lidocaie use i the dorsal had to correct volume deficit is preseted i Tables 4-5. Restylae Lyft with Lidocaie for the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds. There were five US studies that reported adverse evets i support of the idicatio for treatmet of moderate to severe facial folds ad wrikles, such as asolabial folds. I two U.S. studies (i.e., Study MA-4- ad Study MA-4-) ivolvig 433 patiets at 5 ceters, the adverse outcomes reported i patiet diaries durig 4 days after treatmet are preseted i Tables 4. The physicia diagosed adverse evets idetified i these studies at 7 hours after ijectio are preseted i Table 7. I Study MA-4-, 5 patiets were ijected with Perlae o oe side of the face ad Restylae o the other side of the face. I study MA- 4-, 83 patiets were radomized to receive either Perlae or Restylae ijectio o both sides of the face. Table 8 presets all ivestigator-idetified adverse evets recorded at study visits weeks or more after ijectio i studies MA-4-, MA-4-, 3GE ad 3GE. I Study 3GE, 5 Caadia patiets were ijected with both Perlae ad Hylaform. I Study 3GE, 68 Scadiavia patiets uderwet both Perlae ad Zyplast ijectios. I a fifth U.S. study (Study MA-4-3) 6 patiets at three ceters radomly received Restylae Lyft with Lidocaie ijectios o oe side of the face ad Perlae ijectios o the other side of the face. The adverse evets reported i patiet diaries durig 4 days after treatmet are preseted i Tables 5 ad 6. The physicia-recorded adverse evets idetified i study MA-4-3 at 4 days after ijectio are preseted i Table 9. 5 (49)

6 Table. Maximum Itesity of Symptoms after Iitial Treatmet, Patiet Diary (Study MA-4-) Perlae Restylae Perlae Patiets Restylae Patiets Total patiets reportig symptoms Total patiets reportig symptoms Noe Tolerable Affected Daily Activity Disablig Noe Tolerable Affected Daily Activity Disablig Bruisig (86.5%) (78.%) 7 (.%) 97 (69.8%) 4 (7.3%) (.7%) 8 (.%) 8 (59%) 8 (.%) (.7%) Redess 8 (83.7%) 4 (8.3%) (5.%) 5 (75.5%) (8.6%) (.7%) 5 (8%) 96 (69.%) 7 (.%) (.7%) Swellig Pai Tederess Itchig 8 (9.8%) 4 (8.9%) 3 (9.%) 45 (3.9%) 7 (89.4%) 8 (76.%) 3 (86.6%) 67 (47.%) (7.9%) 5 (8%) 9 (6.5%) 94 (67.6%) 7 (77%) 96 (69.%) (8.6%) 4 (8.8%) 9 (3.7%) 8 (.9%) 8 (.9%) 3 (.%) (.4%) (.4%) (8.6%) 3 (.3%) 6 (.5%) 7 (5.8%) (73.4%) 93 (66.9%) 9 (78.4%) 66 (47.5%) 3 (6.5%) 4 (.%) (8.6%) (.7%) (.4%) (.7%) (.4%) Other 3 3 NA NA NA NA NA NA NA NA (.7%) (.%) Missig values are ot reported. Prospective defiitios for: tolerable, affected daily activity ad disablig were ot provided i the diary or protocol. 3 Two patiets reported pimples (oe Perlae/oe Restylae); oe Restylae patiet reported a sore throat; oe Restylae patiet reported a ruy ose; degree of disability was ot reported for ay of the four evets. Bruisig Redess Swellig Pai Tederess Itchig Table. Duratio of Adverse Evets after Iitial Treatmet, Patiet Diary (Study MA-4-) Perlae Restylae Perlae Patiets Restylae Patiets Total patiets reportig symptoms (86.5%) 8 (83.7%) 8 (9.8%) 4 (8.9%) 3 (9.%) 45 (3.9%) Total patiets reportig symptoms (78.%) 4 (8.3%) 7 (89.4%) 8 (76.%) 3 (86.6%) 67 (47.%) 6 (4.9%) 9 (6.%) 6 (4.7%) 46 (4.4%) 4 (8.5%) 9 (4.%) Number of days Number of days -7 8 (66.4%) 87 (73.7%) (78.%) 66 (57.9%) 89 (68.5%) 3 (5.%) (3%) 8 (6.8%) 7 (3.3%) (.8%) 6 (.3%) 3 (6.7%) 4 7 (5.7%) 4 (3.4%) 5 (3.9%) (.8%) 9 (8.%) 3 (7.%) (9.4%) 37 (34.3%) (7.%) (3.8%) (6.%) 7 (6.3%) 93 (73.%) 69 (63.9%) 9 (74.8%) 38 (56.7%) (7%) 9 (7.9%) 9 (5.%) (.9%) 9 (7.3%) 6 (9.%) 4 3 (.7%) 3 (.6%) 3 (.4%) (.8%) (.5%) Other (.7%) (.%) Missig values are ot reported. Data are cumulated from up to four ijectio sites per patiet with earliest ad latest time poit for ay reactio provided. 3 Two patiets reported pimples (oe Perlae/oe Restylae); oe Restylae patiet reported a sore throat; oe Restylae patiet reported a ruy ose; degree of disability was ot reported for ay of the four evets. 6 (49)

7 Table 3. Maximum Itesity of Symptoms after Iitial Treatmet, Patiet Diary (Study MA-4-), Perlae Restylae Perlae Patiets Restylae Patiets Total patiets reportig symptoms Total patiets reportig symptoms Noe Tolerable 3 Affected Daily Activity 3 Disablig 3 Noe Tolerable 3 Affected Daily Activity 3 Disablig 3 Bruisig Redess Swellig Pai Tederess Itchig 74 (49.3%) 9 (6.3%) (8.7%) 3 (68.7%) 3 (86.7%) 58 (38.7%) 7 (46.7%) 87 (58%) 5 (83.3%) 96 (64%) (8.3%) 53 (35.3%) 75 (5.3%) 57 (38.3%) 8 (8.8%) 46 (3.9%) 9 (.8%) 9 (6.%) 67 (45%) 85 (57%) 8 (7.5%) 9 (6.4%) 6 (77.9%) 54 (36.%) 7 (4.7%) 7 (4.7%) (7.4%) (8.%) 3 (8.7%) 4 (.7%) (.3%) (.7%) (.7%) 79 (53%) 6 (4.6%) 4 (6.%) 53 (35.6%) 7 (8.%) 96 (64.4%) 66 (44.3%) 8 (54.4%) 9 (73.%) 84 (56.4%) (73.8%) 49 (3.9%) 4 (.7%) 6 (4%) 4 (9.4%) (7.4%) (7.4%) 4 (.7%) (.3%) (.7%) (.7%) Other NA NA (%) (%) Missig values are ot reported. Evets are reported as local evets; because of the desig (split-face) of the study, causality of the systemic adverse evets caot be assiged. 3 Prospective defiitios for: tolerable, affected daily activity ad disablig were ot provided i the diary or protocol. 4 Two patiets reported mild trasiet headache ad oe patiet reported mild twitchig ; either could be associated with a particular product. Table 4. Duratio of Adverse Evets after Iitial Treatmet, Patiet Diary (Study MA-4-), Bruisig Redess Swellig Pai Tederess Itchig Perlae Restylae Perlae Patiets Restylae Patiets Total patiets reportig symptoms 74 (49.3%) 9 (6.3%) (8.7%) 3 (68.7%) 3 (86.7%) 58 (38.7%) Total patiets reportig symptoms 7 (46.7%) 87 (58%) 5 (83.3%) 96 (64%) (8.3%) 53 (35.3%) Number of days 3 Number of days (3.%) (59.5%) 38 5 (4.3%) (56.5%) 85 (8.%) (7.%) 3 (3.%) 6 (%) 9 (5%) 67 (65%) 94 (7.3%) 6 (44.8%) (8.%) (.%) (9.%) (.9%) 6 (4.6%) (3.4%) 4 (.4%) 3 (.5%) (.9%) 4 (3.%) (.7%) 3 (8.6%) 33 (37.9%) 3 (8.4%) 7 (8.%) 8 (3%) (4.5%) -7 5 (7.9%) 5 (59.8%) 89 (7.%) 67 (69.8%) 87 (7.3%) 7 (5.9%) (8.6%) (.3%) (9.6%) (.%) 7 (5.7%) 4 (7.5%) 4 (.8%) Other (%) (%) Missig values are ot reported. Evets are reported as local evets; because of the desig (split-face) of the study, causality of the systemic adverse evets caot be assiged. 3 Data are cumulated from up to two ijectio sites per patiet with earliest ad latest time poit for ay reactio provided. 4 Two patiets reported mild trasiet headache ad oe patiet reported mild twitchig ; either could be associated with a particular product. 7 (49)

8 Bruisig Redess Swellig Pai Tederess Itchig Table 5. Maximum Itesity of Symptoms after Iitial Treatmet, Patiet Diary (Study MA-4-3) Restylae Lyft with Lidocaie Total patiets reportig symptoms 36 (6.%) 34 (56.7%) 4 (7.%) 8 (46.7%) 5 (83.3%) 6 (6.7%) Perlae Restylae Lyft with Lidocaie Patiets Perlae Patiets Total patiets reportig symptoms 33 (55.%) 3 (5.7%) 39 (65.%) 6 (43.3%) 49 (8.7%) (.%) Noe Tolerable 4 (4.%) 6 (43.3%) 8 (3.%) 3 (53.3%) (6.7%) 44 (73.3%) 3 (53.3%) 3 (5.7%) 34 (56.7%) 5 (4.7%) 45 (75.%) 5 (5.%) Affected Daily Activity 4 (6.7%) 3 (5.%) 8 (3.3%) 3 (5.%) 5 (8.3%) (.7%) Disablig Noe Tolerable (.%) (.%) (.%) (.%) (.%) (.%) 7 (45.%) 9 (48.3%) (35.%) 34 (56.7%) (8.3%) 48 (8.%) 9 (48.3%) 9 (48.3%) 34 (56.7%) 4 (4.%) 47 (78.3%) (.%) Affected Daily Activity 4 (6.7%) (3.3%) 5 (8.3%) (3.3%) (3.3%) (.%) Disablig (.%) (.%) (.%) (.%) (.%) (.%) Other 3 3 (5.%) (.7%) NA NA NA NA NA NA NA NA Missig values are ot reported. Prospective defiitios for: tolerable, affected daily activity ad disablig were ot provided i the diary or protocol. 3 Other icluded symptoms of ace, lumpiess, ad red/purple mark. Diary etries of hurts to swallow, lack of eergy, feelig of sickess, achy, headache, ad broke capillaries could ot be associated with a particular product. Bruisig Redess Swellig Pai Tederess Itchig Table 6. Duratio of Adverse Evets after Iitial Treatmet, Patiet Diary (Study MA-4-3) Restylae Lyft with Lidocaie Total patiets reportig symptoms 36 (6.%) 34 (56.7%) 4 (7.%) 8 (46.7%) 5 (83.3%) 6 (6.7%) Perlae Restylae Lyft with Lidocaie Patiets Perlae Patiets Total patiets reportig symptoms 33 (55.%) 3 (5.7%) 39 (65.%) 6 (43.3%) 49 (8.7%) (.%) 6 (6.7%) 9 (6.5%) 4 (9.5%) 7 (6.7%) 6 (.%) 5 (3.3%) Number of days 3 Number of days (75.%) 4 (7.6%) 33 (78.6%) (39.3%) 4 (8.%) (6.5%) (8.3%) (.%) 4 (9.5%) (.%) 4 (8.%) (6.3%) 4 (.%) (.9%) (.4%) (.%) (.%) (.%) 5 (5.%) 9 (9.%) 6 (5.4%) 5 (57.7%) 8 (6.3%) 5 (4.7%) -7 3 (69.7%) 8 (58.%) 9 (74.4%) (4.3%) 35 (7.4%) 7 (58.3%) (.%) 3 (9.7%) 3 (7.7%) (.%) 6 (.%) (.%) 4 (3.%) (3.%) (.6%) (.%) (.%) (.%) Other,4 3 3 (5.%) (.7%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) (.%) Missig values are ot reported. Evets are reported as local evets; because of the desig (split-face) of the study, causality of the systemic adverse evets caot be assiged. 3 Data are cumulated from up to two ijectio sites per patiet with earliest ad latest time poit for ay reactio provided. 4 Other icluded symptoms of ace, lumpiess, ad red/purple mark. Diary etries of hurts to swallow, lack of eergy, feelig of sickess, achy, headache, ad broke capillaries could ot be associated with a particular product. 8 (49)

9 Table 7 shows the umber of adverse evets idetified by ivestigators at 7 hours after ijectio for Studies MA-4- ad MA-4-. Some patiets had multiple adverse evets or had the same adverse evet at multiple ijectio sites. No adverse evets were of severe itesity. Table 7. All Ivestigator-Idetified Adverse Evets (7 Hours) Number of Evets per Patiet per Study Study Term MA-4- MA-4- Number of Evets Perlae (=5) Number of Evets Restylae (=5) Number of Evets Perlae (=4) Number of Evets Restylae (=4) Ecchymosis Edema Erythema Tederess Pai Hyperpigmetatio 3 Pruritus Papule Burig Hypopigmetatio Ijectio site scab 3 Table 8 presets the umber of patiets ad per patiet icidece of all adverse evets idetified by ivestigators at visits occurrig two or more weeks after ijectio. Study Term Ecchymosis Edema Erythema Tederess Pai Papule Pruritus Rash Hyperpigmetatio Ijectio site scab Ski exfoliatio Table 8. Ivestigator-Idetified Adverse Evets ( Weeks or More After Implatatio) (Number of Patiets) (Perlae v. Specified Active Cotrols All Studies) MA-4- Perlae (=5) 7 (4.6%) (.3%) (.7%) 7 (4.7%) MA-4- Restylae (=5) 4 (.7%) (.3%) (.7%) (.7%) 8 (5.3%) (.7%) MA-4- Perlae (=4) 5 (.6%) 3 (.%) (.4%) (.7%) (.7%) MA-4- Restylae (=4) 4 (9.9%) (.4%) (.7%) (.7%) (.4%) (.7%) 3GE Perlae (=5) 6 (4.%) 4 (9.3%) 3 (8.7%) (.3%) 3 (8.7%) (7.3%) (.3%) (.7%) 3GE Hylaform (=5) (.3%) 6 (4.%) 8 (5.3%) 3 (.%) (.7%) 3 (.%) (.7%) 3GE Perlae (=68) 4 (5.9%) 6 (8.8%) (.5%) 3 (4.4%) 3GE Zyplast (=68) 9 (3.%) 8 (.8%) (.9%) 6 (8.8%) 5 (7.4%) 9 (49)

10 I two studies (i.e., 3GE ad 3GE) with repeat admiistratio of Perlae at 6 9 moths followig the iitial correctio, the icidece ad severity of adverse evets were similar i ature ad duratio to those recorded durig the iitial treatmet sessios. I all four studies, ivestigators reported the followig local ad systemic evets that were judged urelated to treatmet ad occurred at a icidece of less tha %, i.e., ace; tooth disorders (e.g., pai, ifectio, abscess, fracture); dermatitis (e.g., rosacea, uspecified, cotact, impetigo, herpetic); urelated ijectio site reactios (e.g., desquamatio, rash, aesthesia); facial palsy with coadmiistratio of botulium toxi; headache/migraie; ausea (with or without vomitig); sycope; gastroeteritis; upper respiratory or iflueza-like illess; brochitis; siusitis; pharygitis; otitis; viral ifectio; cystitis; diverticulitis; ijuries; laceratios; back pai; rheumatoid arthritis; ad various medical coditios such as chest pai, depressio, real stoes, ad uterie fibroids. Table 9 shows the umber of adverse evets idetified by ivestigators durig Day through Day 4 after ijectio i Study MA-4-3. Table 9. All Ivestigator-Idetified Adverse Evets (4 Days) Number of Evets per Patiet per Study Study Term Number of Evets Restylae Lyft with Lidocaie (=4) MA-4-3 Number of Evets Perlae (=4) Ecchymosis 9 3 Edema 4 4 Erythema 5 5 Pai 4 4 Papule Pruritus 9 5 Tederess 3 3 Some patiets had multiple adverse evets or had the same adverse evets at bilateral ijectio sites. No adverse evets were of severe itesity. Patiets were queried o adverse evets o the day of ijectio ad at the Day 4 visit. Study MA-4-3, icluded 47 subjects who had o prior cosmetic treatmet ad 3 subjects who had prior dermal filler treatmet. There were o statistical differeces i the proportio of subjects with adverse evets who had prior treatmet ad those with o prior treatmet. Table. MA-4-3 Related AE by prior procedure. By Subjects Related AE Prior procedure p-value* Yes No Yes 9 (69.%) 4 No 3 (66.%) 6 * Fisher s exact test. The safety ad effectiveess of Perlae i the treatmet of facial folds ad wrikles (asolabial folds ad oral commissures) were evaluated i four prospective radomized cotrolled cliical studies ivolvig 59 Perlae-treated patiets. (49)

11 Perlae was show to be effective whe compared to cross-liked collage ad cross-liked hyaluroic acid dermal fillers with respect to the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds. The safety ad pai reductio effect of Restylae Lyft with Lidocaie i the treatmet of facial folds ad wrikles (asolabial folds) was evaluated i a prospective radomized cotrolled cliical study ivolvig 6 patiets. The additio of lidocaie to Perlae resulted i a statistically sigificat reductio i the pai experieced by the patiets. The study also showed that the safety profile of Restylae Lyft with Lidocaie was cosistet with Perlae. Restylae Lyft with Lidocaie for cheek augmetatio ad correctio of midface cotour deficiecies i patiets over the age of. Oe U.S. study reported adverse evets i support of Restylae Lyft with Lidocaie for the idicatio of cheek augmetatio ad correctio of midface cotour deficiecies. I the U.S. pivotal study (MA-4-5) ivolvig patiets at ceters, patiets received Restylae Lyft with Lidocaie i both the right ad left midface at baselie or i the cotrol group at Moth. Subjects were asked to record symptoms of bruisig, redess, swellig, pai, tederess ad itchig i a 4-Day patiet diary. Subject s scores for the severity of these evets are preseted i Table ad duratios are provided i Table. The majority of evets were mild cosidered tolerable ad resolved i 7 days. Bruisig teded to have a loger duratio with the majority of subjects resolvig betwee 8 ad 4 days. (49)

12 Table. MA-4-5 Overall Summary of Selected Adverse Evets* as Reported i Subject s Diary by Maximum Severity Safety Populatio No Treatmet at Baselie (N=49) Treatmet Group First Treatmet Secod Treatmet with with Restylae Restylae Lyft with Lyft with Lidocaie Lidocaie (N=99) (N=8) Right ad Left Midface Combied (N=98) Maximum Severity Reported for ay Diary Symptom Noe 47 (96%) 3 (%) (<%) Tolerable (4%) 46 (74%) 94 (74%) Affects Daily Activities 45 (3%) 6 (%) Disablig 4 (%) 6 (5%) Pai (Icludig Burig) Noe 48 (98%) 4 (%) 8 (%) Tolerable (%) 34 (68%) 84 (66%) Affects Daily Activities 3 Disablig (<%) (%) Tederess Noe 49 9 (5%) (8%) Tolerable 7 (86%) 4 (8%) Affects Daily Activities 7 (9%) (9%) Disablig (<%) (<%) Redess Noe (%) 7 (%) Tolerable 39 (7%) 88 (69%) Affects Daily Activities 6 (8%) (8%) Disablig (%) Bruisig Noe (8%) 8 (%) Tolerable 3 (66%) 79 (6%) Affects Daily Activities 3 (6%) 6 (3%) Disablig (<%) 4 (3%) Swellig Noe (4%) Tolerable 45 (73%) 94 (74%) Affects Daily Activities 3 (5%) (9%) Disablig 4 (%) 4 (3%) Itchig Noe 48 (98%) 3 (66%) 9 (7%) Tolerable (%) 63 (3%) 33 (6%) Affects Daily Activities 3 (%) (<%) Disablig (<%) (<%) Note: Percetages are based o the umber of Subjects i the Safety Populatio with ay o-missig assessmet for locatio ad parameter (if applicable). Note: For right ad left combied, the overall maximum severity is take as the maximum of overall right severity ad overall left severity. The combied maximum severity withi symptom category is take as the maximum of right severity ad left severity withi the symptom category. *Selected Adverse Evets are those that were pre-listed i the diary (bruisig, redess, swellig, pai, tederess, itchig) ad required a recordig of oe or the presece ad extet. These diary recordigs were hadled separately from adverse evets that were elicited from a iterview about ay medical occurrece that meets the defiitio of Adverse Evet. (49)

13 Table : Duratio of Selected Adverse Evets* as Reported i the Subject s Diary Safety Populatio No Treatmet at Baselie (N = 49) Number of Days -7 Locatio/ Adverse Evet Ay 8-3 Right ad Left Midface Combied Pai (Icludig Burig) (%) Tederess Redess Bruisig Swellig Itchig (%) First Treatmet with Restylae Lyft with Lidocaie (N = 99) Number of Days 4 Locatio/ Adverse Evet Ay Pai (Icludig 57(79%) 34 (%) 9 (69%) (8%) Burig) Tederess 89(95%) 7 (9%) (59%) 47 (5%) 3 (7%) Redess 55(78%) 39 (5%) 96 (6%) 8 (%) Bruisig 63(8%) (6%) 66 (4%) 7 (43%) 7 Swellig 79(9%) 4 (8%) 3 (74%) 6 (5%) 7 (4%) Itchig 67(34%) 6 (4%) 4 (63%) 9 (3%) Secod Treatmet with Restylae Lyft with Lidocaie (N=8) Number of Days Locatio/ Adverse Evet Ay Pai (Icludig 99 (77%) 7 (7%) 7 (7%) (%) Burig) Tederess 7 (9%) 9 (8%) 7 (6%) 9 (5%) 8 (7%) Redess (78%) 9 (9%) 67 (67%) 3 (3%) Bruisig 99 (77%) 5 (5%) 46 (46%) 35 (35%) 3 (3%) Swellig 9 (85%) 5 (4%) 7 (66%) (8%) (%) Itchig 35 (7%) 9 (6%) 9 (54%) 5 (4%) (6%) ¹ Percetages are based o the umber of subjects i the Safety populatio. Note: Note: Percetages for duratio categories are based o the umber of subjects reportig the symptom ( Ay ) for the specified locatio, uless otherwise oted. Secod Treatmet with Restylae Lyft with Lidocaie colum oly icludes diary summaries from subjects who actually received a secod treatmet at Moth. *Selected Adverse Evets are those that were pre-listed i the diary (bruisig, redess, swellig, pai, tederess, itchig) ad required a recordig of oe or the presece ad extet. These diary recordigs were hadled separately from adverse evets that were elicited from a iterview about ay medical occurrece that meets the defiitio of Adverse Evet. Midface safety assessmets, such as firmess, symmetry, fuctio (movemet), mass formatio ad sesatio were evaluated at the screeig visit, optioal touch up visit, week follow up visit, 4 week follow up visit,,4,6,8 ad moth follow up visits, ad the moth follow up visit. I additio, midface safety assessmets, such as firmess, symmetry, fuctio, mass formatio ad sesatio were evaluated at the followig moth post treatmet visits: optioal touch up visit, week post-treatmet visit, 4 week post-treatmet visit, ad the week post-treatmet visit. Device palpability was assessed at each scheduled visit listed above with the exceptio of the screeig visit. Oe subject reported greater tha mild for the midface safety assessmets of firmess, symmetry, fuctio, mass formatio ad abormal device palpability. This subject reported a mild hematoma i the right cheek startig five days after the iitial treatmet that progressed to a moderate hematoma startig 6 days later ad lastig 6 days. Reported treatmet icluded atibiotics. The ivestigator believed that the hematoma was exacerbated by self-maipulatio. 3 (49)

14 There were o sigs of iflammatio i subjects reportig mild or moderate abormality i the safety assessmets of midface. The physicia diagosed adverse evets idetified i this study are preseted i Table 3. Of the subjects erolled i the study, 99 subjects received their first treatmet with Restylae Lyft with Lidocaie at either baselie/day or at Moth, ad 8 subjects received a secod treatmet at Moth. Forty-ie percet (49%) of subjects receivig their first treatmet reported a total of 69 TEAEs while 9% of subjects that received a secod treatmet reported a total of 77 TEAEs. The majority of these TEAEs were mild i itesity (/69; 79%, ad 7/77; 9%; first ad secod treatmet respectively), ad were trasiet i ature. The most commo TEAEs occurrig after iitial treatmet with Restylae Lyft with Lidocaie were implat site haematoma (8%), implat site haemorrhage (5%), implat site pai (9%), implat site swellig (8%), ad headache (7%). There was o icreased risk with additioal treatmet with Restylae Lyft with Lidocaie. Subjects with Fitzpatrick Ski Types IV, V ad VI (=6) ad had safety results similar to the geeral study populatio. Table 3. MA-4-5 Summary of Treatmet Emerget Adverse Evets Occurrig i % of Treated Subjects Safety Populatio No Treatmet at Baselie (N=5) Treatmet Group First Treatmet with Restylae Lyft with Lidocaie (N=99) Secod Treatmet with Restylae Lyft with Lidocaie (N=8) Evets Subjects Evets Subjects Evets Subjects Ay TEAE 8 5 (3%) (48.7%) (8.9%) Geeral Disorders ad Admiistratio Site Coditios Implat Site Haematoma 5 36 (8%) 8 (8%) Implat Site Haemorrhage 8 (5%) 9 (7%) Implat Site Mass 6 5 (.5%) (.8%) Implat Site Pai 36 7 (9%) 6 (5%) Implat Site Swellig 36 5 (8%) 6 4 (3%) Ifectios ad Ifestatios Nasopharygitis (%) 4 4 (%) Upper Respiratory Tract 4 4 (%) Ifectio Nervous System Disorders Headache 3 3 (6%) 4 3 (7%) (<%) Hypoaesthesia 5 4 (%) ¹ A subject with more tha oe treatmet emerget adverse evet withi a system orga class ad/or preferred term is oly couted oce. Note: For the No Treatmet at Baselie group a adverse evet is cosidered treatmet emerget if the start date is o or after the Visit (Day ) date. For the First Treatmet with Restylae Lyft with Lidocaie group a adverse evet is cosidered treatmet emerget if the start date is o or after the date of iitial treatmet ijectio ad before the date of Moth ijectio. For the Secod Treatmet with Restylae Lyft with Lidocaie group a adverse evet is cosidered treatmet emerget if the start date is o or after the date of the Moth ijectio. Two subjects (%, /99) reported four serious adverse evets (SAEs) that were cosidered to be related to the device ad/or the procedure. Oe subject reported implat site iflammatio (late oset iflammatory reactios) i both cheeks at separate times. The secod subject experieced implat site hematomas i the right cheek ad implat site ifectio/abscess. Treatmet of the SAEs icluded NSAIDs, atibiotics, icisio ad draiage ad, hyaluroidase. All evets resolved. 4 (49)

15 Approximately 3% of subjects had a delayed oset (> days after treatmet) of implat site erythema, implat site hematoma, implat site iflammatio, implat site mass, implat site pai, implat site swellig, implat site warmth, iduratio, twitchig or rosacea that occurred up to 38 days after treatmet. Adverse evets associated with the use of the device ad occurrig i < % of subjects whether related or ot related were suke eyes, ausea, implat site ifectio/abscess, implat site iflammatio, implat site mass, implat site warmth, implat site irritatio, iduratio, muscle tightess, muscle twitchig, pai i jaw, presycope, 7th erve paralysis, ace, eedle track marks, rosacea, cojuctivitis, eyelid cyst, colitis ischemic, detal carries, gigival swellig, tooth ache, cyst, discomfort, ijectio site pai, geeral swellig, ulcer, acarodermatitis, brochitis, eye ifectio, implat site cellulitis, iflueza, oral herpes, peumoia, soft tissue ifectio, arthropod stig, icisio site pai, exposure to toxic aget, facial ijury, ligamet sprai, meiscus lesio, thermal bur, tooth fracture, type diabetes, arthralgia, back pai, bursitis, myalgia, eck pai, pai i extremity, basal cell carcioma, pacreatic carcioma, metastatic carcioma, carpal tuel sydrome, abortio spotaeous, depressio, prostatitis, pulmoary vascular disorder, dermatitis cotact, rash, urticaria, eurectomy, ad hypertesio. Restylae Lyft with Lidocaie for ijectio ito the subcutaeous plae i the dorsal had to correct volume deficit i patiets over the age of. Oe U.S. study was coducted i support of Restylae Lyft with Lidocaie for ijectio i the dorsal had to correct volume deficit i patiets over the age of. Cliical study 43USH5 was a prospective, multi-ceter, radomized, evaluator-blided, paired (split-had) study desiged to evaluate the safety ad efficacy of Restylae Lyft with Lidocaie for ijectio i the dorsal had to correct volume deficit i patiets over the age of. The study was coducted at 5 ivestigatioal sites ad icluded 89 patiets who were ijected with a Terumo 9G x ½ thi-walled sharp eedle. For eedle subjects oly, adverse evets were recorded i subject diaries (8 days post-treatmet) as well as by physicia evaluatios. Subjects were asked to record symptoms of bruisig, redess, swellig, pai, tederess, itchig, ad impaired had fuctio i a 8-Day patiet diary. Subject s scores for the severity of these evets are preseted i Table 4 ad duratios are provided i Table 5. After the first ijectio, most evets resolved withi the first week ad most reactios reported were mild. 5 (49)

16 Table 4: Maximum Itesity of Post-Treatmet Ijectio Site Reactios Recorded i the Subject Diary (Safety Populatio) Evet Severity Iitial Treatmet 6 Moth Treatmet Restylae Lyft had Fellow Had Restylae Lyft had Fellow Had Touch-Up No Treatmet a Re-treatmet Treatmet (N=74) b (N=89) b (N=7) (N=77) Treatmet (N=89) b Touch-Up (N=44) Bruisig Total 53 (6.%) 37 (5.7%) (.%) 9 (4.4%) 48 (6.3%) 7 (38.6%) Mild 43 (48.9%) 3 (43.8%) (.%) 3 (3.9%) 3 (4.6%) 3 (9.5%) Moderate (.4%) 5 (6.8%) 6 (8.6%) 5 (9.5%) 4 (9.%) Severe (.3%) Itchig Total (3.6%) 7 (9.6%) 8 (.4%) (3.%) (.7%) Mild (.5%) 6 (8.%) 6 (8.6%) 6 (7.8%) (.7%) Moderate (.%) (.4%) (.9%) 4 (5.%) Severe Pai Total 39 (44.3%) 6 (35.6%) 3 (4.9%) 4 (54.5%) (5.%) Mild 3 (34.%) 5 (34.%) (8.6%) 6 (33.8%) 8 (8.%) Moderate 8 (9.%) (.4%) (4.3%) 3 (6.9%) (4.5%) Severe (.%) 3 (3.9%) (.3%) Redess Total 63 (7.6%) 4 (56.%) 4 (6.%) 5 (64.9%) (45.5%) Mild 5 (59.%) 39 (53.4%) 34 (48.6%) 33 (4.9%) 9 (43.%) Moderate (.5%) (.7%) 7 (.%) 6 (.8%) (.3%) Severe (.4%) (.3%) Swellig Total 66 (75.%) 43 (58.9%) (.%) 3 (44.3%) 47 (6.%) (5.%) Mild 45 (5.%) 34 (46.6%) (.%) 8 (5.7%) 7 (35.%) 6 (36.4%) Moderate 9 (.6%) 9 (.3%) (7.%) 9 (4.7%) 5 (.4%) Severe (.3%) (.4%) (.3%) (.3%) Tederess Total 66 (75.%) 49 (67.%) (.3%) 4 (58.6%) 55 (7.4%) 6 (59.%) Mild 5 (58.%) 4 (57.5%) (.3%) 8 (4.%) 3 (4.3%) (47.7%) Moderate 4 (5.9%) 7 (9.6%) (5.7%) (6.%) 4 (9.%) Severe (.%) (.9%) 4 (5.%) (.3%) Impaired Fuctio Total 6 (6.8%) 3 (4.%) 3 (4.3%) 8 (.4%) (.3%) a Four subjects reported ijectio site reactios o the fellow had durig the o treatmet phase. b Oe subject did ot had i the diary from the Iitial treatmet (first treatmet ad touch-up) 6 (49)

17 Table 5: Number of Days with Post-Treatmet Ijectio Site Reactios Recorded i the Subject Diary (Safety Populatio) Evet Statistic Iitial Treatmet 6 Moth Treatmet Restylae Lyft had Fellow Had Restylae Lyft had Fellow Had Touch-Up No Treatmet a Re-treatmet Treatmet (N=74) (N=89) (N=7) (N=77) Treatmet (N=89) Touch-Up (N=44) Bruisig N Mea SD N/A Media Mi. to Max. to 8 to 8 to to 7 to 7 to 7 Itchig N 7 8 Mea SD Media Mi. to Max. to 3 to 4 to to 9 to 4 Pai N Mea SD Media Mi. to Max. to to 5 to 8 to 9 to Redess N Mea SD Media..... Mi. to Max. to 7 to to 6 to 7 to 9 Swellig N Mea SD N/A Media Mi. to Max. to 6 to to to 8 to 5 to Tederess N Mea SD Media Mi. to Max. to 7 to 7 to to 8 to 7 to 4 Impaired Fuctio N Mea SD N/A Media Mi. to Max. to 4 to to 3 to 5 to a Four subjects reported ijectio site reactios o the fellow had durig the o treatmet phase. 7 (49)

18 Had fuctio safety assessmets, icludig rage of motio, fuctioal dexterity, pich ad grip stregth, ad sesatio were evaluated at all required study follow up visits. Passive ad active rage of motio testig i the figers (extesio) revealed egligible chage. I the active flexio test for the thumb, there was slightly reduced flexio after treatmet. There were subjects out of 89 (4.7%) ijected with eedle that had at least -degree egative chage of active flexio for thumb of the treated had compared to baselie or o-treated had that remai through the duratio of the study. A summary is provided i Table 6. There was o evidece of loss of sesatio for ay subject throughout the course of the study. Stregth tests revealed o appreciable loss of stregth for the grip ad pich stregth tests. Table 6: Active Flexio Rage of Thumb Data for Subjects with at least -degree egative chage Patiet ID Start Visit of First Episode Number of Episodes Duratio of Logest Episode (Days) Patiet Week 6 76 Patiet Week followig touch-up >4 Patiet 3 Week followig touch-up 36 Patiet 4 Week 3 >4 Patiet 5 Week 4 Patiet 6 Week 4 >76 Patiet 7 Week >86 Patiet 8 Week 4 followig touch-up 6 Patiet 9 Week >5 Patiet Week 6 37 Patiet Week 3 84 Patiet Week 7 Patiet 3 Week >89 Patiet 4 Week 9 Patiet 5 Week 6 5 Patiet 6 Week 3 Patiet 7 Week 3 Patiet 8 Week > Patiet 9 Week 9 Patiet Week 4 8 Patiet Week 4 followig touch-up 8 Patiet Week Note: Episode duratio is calculated as study day for first visit with o decrease i Active Flexio Rage of Thumb after a episode, MINUS study day with first decrease i Active Flexio Rage of Thumb. Note: > idicates that there is o assessmet with o decrease i Active Flexio Rage of Thumb for a episode, ad istead the last study day is used as stop day. 8 (49)

19 Results from subject assessmet of the had-specific impact o daily life activities usig the uvalidated moolateral Michiga Had Questioaire (MHQ) showed a egligible effect o subject s daily life activities. The majority of subjects respoded with favorable aswers to all questios at each study visit assessed (Baselie, Week, ad Week 4). The majority of subjects were dissatisfied with the appearace of their hads at Baselie with a shift i respose to satisfactio at Weeks ad 4. A total of 37 (4.6%) subjects experieced at least oe Treatmet Emerget Adverse Evet (TEAE), i total 8 evets. The majority of TEAEs were mild i itesity (N=66 mild, 6 moderate, ad o severe). There were o SAEs related to the study product or procedure reported i this trial. A summary of all Treatmet Emerget Adverse Evets (TEAEs) ca be see i Table 7. Table 7: Treatmet Emerget Adverse Evets by Itesity ad Preferred Term (Safety Populatio N=89) Number of Preferred Term Grade of Itesity Number Subjects Mild Moderate Severe of Evets % Vitreous detachmet... Cyst rupture... Device failure... Facial pai... Iflueza like illess... Peripheral swellig Brochitis.. Chroic siusitis... Gastroeteritis... Nasopharygitis... Oychomycosis... Oral herpes... Siusitis... Tooth ifectio.. Upper respiratory tract... ifectio Aimal scratch... Burs first degree... Cotusio. 3. Eye ijury... Laceratio Limb ijury... Nail ijury... Scratch Thermal bur... Blood cholesterol icreased... Vitami D deficiecy... Back pai... Muscle spasms... Musculoskeletal pai... 9 (49)

20 Preferred Term Grade of Itesity Number Number of Subjects Mild Moderate Severe of Evets % Pai i extremity Rotator cuff sydrome... Basal cell carcioma... Lobular breast carcioma i... situ Thyroid eoplasm... Uterie leiomyoma... Migraie... Uriary tract ifectio... Uterie polyp... Cough... Actiic keratosis... Dermatitis cotact... Eczema... Oycholysis... Photosesitivity reactio... Pruritus... Rash... Ski mass... Urticaria... Adverse evets that occurred i >.5% of the study populatio cosisted of peripheral swellig [4 subjects (4.5%)], laceratio [6 subjects (6.7%)], scratch [(6 subjects (6.7%)], ad pai i extremity [5 subjects (5.6%)] with the majority of TEAEs beig mild i itesity (N=66 mild, 6 moderate, ad o severe). Of the 37 subjects reportig a TEAE, 7 subjects (7/89 [7.9%]) reported TEAEs classified as related to the product ad/or ijectio procedure (with 3 total related evets). For the 89 subjects i the Safety populatio, three had-specific related TEAEs were reported i 3 subjects (3/89, 3.4%) after first treatmet (first treatmet i the radomized had) ad icluded peripheral swellig (/89,.%), ad ski mass (/89,.%). I the secod treatmet (treatmet i fellow [o-radomized] had), 5 had-specific related TEAEs were reported i 3 subjects (3/77, 3.9%) ad icluded peripheral swellig (/77,.6%), pai i extremity (/77,.6%), ad pruritis (/77,.3%). Four had-specific related TEAEs were reported i subjects (/7,.9%) i the 3rd treatmet (Retreatmet at 4 weeks). Of the 7 subjects with product/ijectio procedure related TEAEs, 4 subjects received medical treatmet. Treatmet icluded NSAIDS, oral atihistamies, topical ad oral corticosteroids, hyaluroidase, ad atibiotics. Five of these 7 subjects experieced delayed oset (> days) related TEAEs ad additioal subjects reported delayed oset related AEs after exit from the study The delayed adverse evets were mild to moderate ad icluded swellig, odules, tederess, itchig, tiglig, ad erythema. Four of these subjects received treatmet as metioed above. All evets were followed to resolutio. A summary of all Delayed Treatmet Emerget Adverse Evets (TEAE) ca be see i Table 8. (49)

21 Table 8: Delayed Oset Treatmet Emerget Adverse Evets (TEAE) Patiet Patiet Patiet 3 Patiet 4 FST TYPE III TYPE III TYPE III TYPE III Ijectio method AE start day rel. last trt AE duratio Needle 3 89 MILD SINGLE SUB- CUTANEOUS NODULE Severity Itesity Reported AE term Treatmet of the AE Needle 8 5 MILD ITCHING ON THE DORSUM OF THE LEFT HAND 8 5 MILD ITCHING ON THE DORSUM OF THE RIGHT HAND 8 5 MILD SWELLING TO THE DORSUM OF THE LEFT HAND 8 5 MILD SWELLING TO THE DORSUM OF THE RIGHT HAND 8 5 MILD TENDERNESS TO THE DORSUM OF THE LEFT HAND 8 5 MILD TENDERNESS TO THE DORSUM OF THE RIGHT HAND Needle 48 5 MODERATE SWELLING TO THE DORSUM OF THE LEFT HAND 5 MODERATE SWELLING TO THE DORSUM OF THE RIGHT HAND Needle 7 96 MILD PROLONGED SWELLING OF THE DORSUM OF THE RIGHT HAND Noe Noe Noe Noe Noe Noe Noe Ibuprofe, Chloreiramie Maleate, Hydrocortisoe Cream, Medrol Dose Pack, Hyaluroidase, Bethamethasoe Dipropiate Ibuprofe, Chloreiramie Maleate, Hydrocortisoe Cream, Medrol Dose Pack, Hyaluroidase, Bethamethasoe Dipropiate Ibuprofe (49)

22 Patiet 5 Patiet 6* Patiet 7* FST TYPE V TYPE II TYPE IV Ijectio method AE start day rel. last trt AE duratio Severity Itesity Reported AE term Treatmet of the AE Needle 5 49 MILD SWELLING TO THE DORSUM OF THE LEFT HAND Needle 3 36 MILD GRANULOMA Noe Beadryl Cream, Hydrocortisoe Cream, Methlypredisoloe, Sulfamethoxazole, Hyaluroidase, Ice Needle 4 MODERATE SWELLING Medrol Dose Pack *Idicates the adverse evet reported post-study exit. (49)

23 Caula Cohort Results A cohort study with caula ijectio of Restylae Lyft with Lidocaie was performed o 5 subjects (4 FST I-IV subjects ad FST V-VI subjects) i two U.S. sites. The beefits ad risks of ijectig Restylae Lyft with Lidocaie usig a caula for the had idicatio have ot bee established. The study was ot desiged or powered to assess the safety ad effectiveess of the use of caula or to compare its performace to the use of a eedle. Prelimiary results idicate that caula use was associated with higher umber of TEAEs, delayed adverse evets ad egative chage i the active flexio for thumb as compared to eedle ijectios. However, it was ot possible to cotrol or adjust for importat potetial cofouders such as ijectio techiques, caula size, ad physicia s skills. Rates of TEAE were higher i the caula cohort (4 evets i 7 of 5 caula-ijected subjects, 7/5 = 68.%) compared to those rates observed i subjects who received Restylae Lyft with Lidocaie admiistered with eedle (8 evets i 37 of 89 eedle-ijected subjects, 37/89 = 4.6%). Whe the device was ijected with eedle (N=89) had-specific related TEAEs were reported ad 3 of them were related to the st treatmet (3 evets occurred i 3 subjects, 3/89 = 3.3%) compared with Caula ijectio (N=5) where 5 had-specific related TEAEs i 7 subjects were reported related to the st treatmet (5 evets occurred i 7 subjects, 7/5 = 8%). Regardig delayed adverse evets, there appeared to be higher rates of delayed AE i the subjects who received Restylae Lyft with Lidocaie with caula compared to those who received eedle. I 3 subjects with delayed AEs (> day after treatmet), 6 subjects who had Needle ijectio had delayed AE (6/89 = 6.7%) ad 7 subjects who received Caula ijectio experieced delayed AE (7/5 = 8%). Regardig egative chage i the active flexio for thumb, there were subjects out of 89 (4.7%) ijected with the eedle that had at least a -degree egative chage of actio flexio for thumb of the treated had compared to baselie or o-treated had that remai through the duratio of the study. There were 9 subjects out of 5 (36%) ijected with the caula that had at least a -degree egative chage of actio flexio for the thumb of the treated had compared to baselie or otreated had that remai through the duratio of the study. Post-Marketig Surveillace The adverse evet reports received from post-marketig surveillace (from volutary reportig ad published literature) for the use of Restylae Lyft with Lidocaie ad Perlae for all idicatios (icludig cheek) icluded reports of swellig/oedema or iflammatory reactios immediate or delayed oset, up to several weeks after treatmet. The followig evets were also reported: short duratio of effect, mass formatio icludig lumps or bumps, iduratio, pai or tederess, erythema, bruisig/hematoma, presumptive bacterial ifectios ad abscess formatio, papules or odules, iflammatio, ijectio site reactios icludig burig sesatio, warmth ad irritatio, discoloratio/hyperpigmetatio, eurological symptoms icludig hypoaesthesia, paraesthesia ad facial erve paralysis, hypersesitivity, agioedema, ischemia ad ecrosis due to uitetioal itravascular ijectio or embolisatio, eye disorders icludig eye pai, eye swellig, eye irritatio, icreased lacrimatio, eyelid ptosis ad visual impairmet such as blurred visio, reduced visual acuity ad blidess, pruritus, atrophy/scarrig, device dislocatio, rash, effusio/discharge, grauloma/foreig body reactio, ace, blisters/vesicles, symptoms of reactivatio of herpes ifectio, urticaria, capillary disorder such as telagiectasia, extrusio of device, dermatitis, muscle disorders such as muscle twitchig ad muscle weakess, ecapsulatio ad other dermatological evets icludig dry ski, ski wriklig, ski exfoliatio ad localized alopecia, ad o- 3 (49)

24 dermatological evets icludig headache, discomfort, malaise, pyrexia, dizziess, siusitis, dyspoea, fatigue, iflueza like illess, isomia, ausea ad axiety. Whe required, treatmets for these evets icluded ice, massage, warm compress, itroglycerie paste, corticosteroids, atibiotics, aticoagulats, atihistamies, aalgesics, ativiral agets, diuretic agets, aspiratio/icisio ad draiage, surgery or ezymatic degradatio (with hyaluroidase) of the product. Adverse evets received from post-marketig surveillace for Restylae Lyft with Lidocaie ad Perlae used for cheek augmetatio was i lie with the reports listed above for all idicatios. I rare cases, a late oset (weeks to moths) ad recurret iflammatio was reported post ijectio. Cocurret localized evets/symptoms were odules or lumps, ifectio, ad redess, swellig ad pai. The treatmets of these evets icluded hyaluroidase, atibiotics, corticosteroids, aalgesics, icisio ad draiage. Reports of serious adverse evets for Restylae Lyft with Lidocaie ad Perlae are rare. The most commoly reported serious adverse evets were ifectio/abscess, ischemia/ecrosis, visual impairmet, hypersesitivity/allergic reactios, scarrig, iflammatio, ad grauloma icludig cases of mass/iduratio. Cocurret serious evets/symptoms icluded: swellig, pai/tederess, erythema, eurological symptoms such as paresthesia ad hypoesthesia, bruisig, discoloratio, papules/odules, ad overcorrectio, overfill ad irregular ski. Serious ifectios/abscesses were reported with a time to oset ragig from oe day to two moths followig the ijectio. Most of the patiets were recovered or recoverig at the time of last cotact. The treatmets icluded atibiotics, aalgesics, corticosteroids ad hyaluroidase. Serious hypersesitivity reactios were reported i most cases with a time to oset ragig from immediately to few weeks post ijectio. Most of the evets were recoverig or recovered at the time of last cotact. The treatmet icluded aalgesics, atihistamie, atibiotics, ad corticosteroids. Serious grauloma/foreig body reactio icludig mass/iduratio, were reported with a time to oset ragig from oe day to a year or loger. The outcomes were mostly recovered or recoverig at the time of last cotact. The treatmet icluded aalgesics, atihistamie, atibiotics, corticosteroids ad excisios. Biopsies have bee take i some cases, but the majority of cases are o-biopsy cofirmed. Serious iflammatio was reported with a time to oset from oe to two weeks post ijectio. Most evets were recovered or recoverig at the time of last cotact. Rare cases of iflammatio with delayed oset up to several weeks or moths post ijectio has bee observed; particularly if the patiet experieced local trauma, facial/detal ifectio, or local ifectio. The treatmet icluded aalgesics, atibiotics, ad corticosteroids. Vascular occlusio resultig i ischemia/ecrosis ad visio disturbaces icludig blidess have bee reported followig ijectio of ay soft tissue filler i the face especially i the ose, glabella, periorbital areas, asolabial folds ad cheek, with a time to oset ragig from immediate to a few weeks followig ijectio. Vascular compromise may occur due to a iadvertet itravascular ijectio or as a result of vascular compressio associated with implatatio of ay ijectable product. This may maifest as blachig, discoloratio, ecrosis or ulceratio at the implat site or i the area supplied by the blood vessels affected; or rarely as ischemic evets i other orgas due 4 (49)

25 to embolisatio. Isolated rare cases of ischemic evets affectig the eye leadig to visual loss, ad the brai resultig i cerebral ifarctio, followig facial aesthetic treatmets have bee reported. Reported treatmets iclude aticoagulat, epiephrie, aspiri, hyaluroidase, corticosteroid treatmet, aalgesics, atibiotics, local woud care, draiage, hyperbaric oxyge ad surgery. Outcome of the evets raged from resolved to ogoig at the time of last cotact. I may of the evets requirig medical itervetio, the patiet was ijected ito the highly vascularized areas of the glabella, ose, ad periorbital area, which are outside the device idicatios for use (See Warigs sectio). Ijectio site bruisig, swellig, erythema ad pai mostly o-serious geerally occurred withi - days after treatmet usually resolvig withi to 4 weeks. Some occurreces have persisted for up to 6 moths. Most istaces of discoloratio icludig hyperpigmetatio, sometimes described as a blue or brow color, have occurred withi the same day as treatmet but have also occurred up to 6 moths post treatmet. These evets typically resolve withi a few days but with some ifrequet istaces lastig up to 8 moths. Adverse reactios should be reported to Galderma Laboratories, L.P. at Cliical Trials Restylae Lyft with Lidocaie is idicated for implatatio ito the deep dermis to superficial subcutis for the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds ad for subcutaeous to supraperiosteal implatatio for cheek augmetatio ad correctio of agerelated midface cotour deficiecies. Restylae Lyft with Lidocaie is also idicated for ijectio ito the subcutaeous plae i the dorsal had to correct volume deficit i patiets over the age of. Cliical trial iformatio for Restylae Lyft with Lidocaie use i the correctio of moderate to severe facial folds ad wrikles, such as asolabial folds is preseted i the sectio titled "U.S. Cliical Studies to support Perlae /Restylae Lyft with Lidocaie i the treatmet of facial folds ad wrikles (asolabial folds ad oral commissures)." Cliical trial iformatio for cheek augmetatio ad correctio of age-related midface cotour deficiecies is preseted i the sectio titled "U.S. Cliical Study to support the use of Restylae Lyft with Lidocaie i cheek augmetatio ad correctio of midface cotour deficiecies". Cliical trial iformatio for correctio of volume deficit i the dorsal had is preseted i the sectio titled U.S. Cliical Study to support the use of Restylae Lyft with Lidocaie for ijectio i the dorsal had to correct volume deficit. U.S. Cliical Studies to support Perlae /Restylae Lyft with Lidocaie i the treatmet of facial folds ad wrikles (asolabial folds ad oral commissures) Desig MA-4-: Prospective, Radomized, Blided, Cotrolled Cliical Study : radomized, prospective study at 7 U.S. ceters, which compared the safety ad effectiveess of Perlae ad Restylae followig treatmet to baselie coditio. Patiets were radomized to either Perlae or Restylae treatmet. A touch-up was allowed weeks after iitial treatmet. Patiets were partially masked; evaluatig physicias were idepedet ad masked; treatig physicias were umasked. Effectiveess was studied with 6 moths follow-up. Safety was studied with 6 moths follow-up. 5 (49)

26 Edpoits Effectiveess Primary: The differece i effect of Perlae at week versus baselie coditio o the visual severity of the asolabial folds, as assessed by the Blided Evaluator. The primary study edpoit was wrikle severity weeks after optimal correctio was achieved. Wrikle severity was evaluated o a five-step validated Wrikle Severity Ratig Scale (WSRS) (i.e., oe, mild, moderate, severe, extreme) by a live evaluator blided to treatmet. Patiet success was defied as maitaiig at least a oe poit improvemet o the WSRS at weeks after optimal correctio was achieved. The percet of patiet successes was calculated for each treatmet group. Each group was compared to its ow baselie, with o compariso of Perlae to Restylae. Secodary: Wrikle Severity Ratig Scale (WSRS) assessed at other follow-up poits (, 6, ad 4 weeks after optimal correctio) by the Blided Evaluator, the ivestigator ad the patiet ad compared to baselie score by the same evaluator. Duratio of effect defied as 6 moths or time poit, if earlier, at which less tha 5% of patiets had at least a -grade respose remaiig i both asolabial folds (NLFs). Safety assessmets icluded: collectio of patiet symptoms i a 4-day diary; ivestigator evaluatio of adverse evets at 7 hours, ad at, 6,, ad 4 weeks; developmet of humoral or cell-mediated immuity; ad the relatioship of adverse evets to ijectio techique. Outcomes Demographics: The study erolled 83 (i.e., 4 Perlae ad 4 Restylae ) patiets with moderate to severe NLF wrikles. The patiets were predomiatly healthy ethically diverse females. Bilateral NLFs ad oral commissures were corrected i most patiets with.9 ml to 4.6 ml of Perlae. The greatest amout used i ay patiet was 9. ml. Geder Female: 66 (94%); Male: 7 (6%) Ethicity White: 6 (8%); Hispaic or Latio: 3 ; Africa America: 3 (8%); Asia: 3 Efficacy: The results of the blided evaluator assessmet of NLF wrikle severity for Perlae ad cotrol (Restylae ) are preseted i Table 9. I the primary effectiveess assessmet at weeks, 87% of the Perlae ad 77% of the cotrol patiets had maitaied at least a poit improvemet over baselie. 6 (49)

27 Table 9. Blided Evaluator Wrikle Severity Respose Scores Time poit No. of Perlae Patiets No. of Perlae Pts. maitaiig Uit Improvemet of NLF o WSRS No. of Restylae Patiets No. of Restylae Pts. maitaiig Uit Improvemet of NLF o WSRS 6 weeks 36 (89%) 36 3 (83%) weeks 4 (87%) 4 8 (77%) 4 weeks (63%) 4 3 (74%) All p-values <. based o t-test compared to baselie coditio Atibody Testig: 5/4 (.6%) patiets displayed a pre-treatmet atibody respose agaist Perlae, (which was believed to be related to co-purifyig Streptococcus capsule atiges). Oe patiet also developed a measurable icrease i atibody titer after Perlae ijectio. 4/6 (7%) patiets with atibodies agaist Perlae had adverse evets at the ijectio site, which was similar to the local adverse evet rate observed i the etire Perlae populatio (i.e., 49/4 (35%)). With the exceptio of oe moderate bruisig evet, all the adverse evets i the patiets with a humoral respose agaist Perlae were mild i severity. No severe evets were oted ad the patiet who developed a atibody respose after Perlae ijectio did ot experiece ay adverse evet at the ijectio site. Immediate type ski testig demostrated that o patiet developed IgE to Perlae. Post-exposure histopathology of ski biopsies of a implat site o each patiet demostrated that o patiet developed cell-mediated immuity to Perlae. 7 (49)

28 Desig MA-4-: Prospective, Radomized, Blided, Cotrolled Cliical Study : radomized, prospective study at U.S. ceters, which compared the safety ad effectiveess of Perlae ad Restylae followig treatmet to baselie coditio i 5 patiets with pigmeted ski ad predomiatly Africa-America ethicity. Patiets were radomized to either Perlae or Restylae treatmet i a withi-patiet model of augmetatio correctio of bilateral asolabial folds (NLFs) ad oral commissures with oe treatmet assiged to oe side ad the other treatmet to the other side. A touch-up was allowed weeks after iitial treatmet. Patiets ad treatig physicias were partially masked. Evaluatios were performed by live ivestigator assessmet for the primary aalysis. Effectiveess was studied with 6 moths follow-up. Safety was studied with 6 moths follow-up. Edpoits Effectiveess Primary: The differece i effect of Perlae at week versus baselie coditio o the visual severity of the NLFs. The primary study edpoit was wrikle severity weeks after optimal correctio was achieved. Wrikle severity was evaluated with a five-step validated Wrikle Severity Ratig Scale (WSRS) (i.e., oe, mild, moderate, severe, extreme) by a o-site Blided Evaluator. Patiet success was defied as maitaiig at least a oe poit improvemet o the WSRS at weeks after optimal correctio was achieved. The percet of patiets success was calculated for each group. Each treatmet group was compared to its ow baselie, with o compariso of Perlae to Restylae. Secodary: Wrikle Severity Ratig Scale (WSRS) was assessed at other follow-up poits (, 6, ad 4 weeks after optimal correctio) by the ivestigator ad the patiet ad compared to baselie score by the same evaluator. A photographic assessmet of patiet outcomes was also performed. Duratio of effect defied as 6 moths or time poit, if earlier, at which less tha 5% of patiets had at least a -grade respose at both asolabial folds. Outcomes Safety assessmets icluded: collectio of patiet symptoms i a 4-day diary; ivestigator evaluatio of adverse evets at 7 hours, ad at, 6,, ad 4 weeks; the developmet of humoral or cell-mediated immuity; ad the relatioship of adverse evets to ijectio techique. Demographics: The study erolled 5 patiets with moderate to severe NLF wrikles. The patiets were predomiatly healthy Africa-America females. Geder Female: 4/5 (93%); Male /5 (7%) 8 (49)

29 Ethicity White: (.3%); Hispaic or Latio: 9 (6%); Africa-America: 37 (9%); America Idia: (.3%) Fitzpatrick Ski Type I to III: ; IV: 44 (9%); V: 68 (45%); VI: 38 (5%) Efficacy: The results of the live blided evaluator assessmet of wrikle severity for Perlae ad cotrol (Restylae ) are preseted i Table ad are based o the Itet-to-Treat aalysis. I the primary effectiveess assessmet at weeks, 9% of the Perlae-treated ad 93% of the Restylae-treated NLF maitaied at least a poit improvemet over baselie. Time poit Table. Live Evaluator Wrikle Severity Respose Scores No. of patiets No. of Perlae Pts. maitaiig Uit Improvemet o WSRS 95% Perlae Cofidece Iterval No. of Restylae Pts. maitaiig Uit Improvemet o WSRS 95% Restylae Cofidece Iterval 6 weeks 48 4 (95%) 9-99 % 4 (96%) 9-99% weeks (9%) 87-97% 39 (93%) 89-98% 4 weeks 47 4 (7%) 63-77% 8 (73%) 66-8% All p-values <. based o t-test compared to baselie coditio Atibody Testig: 6/5 (4%) patiets displayed a pre-treatmet atibody respose agaist Perlae (which was believed to be related to co-purifyig Streptococcus capsule atiges). No patiets developed a measurable icrease i atibody titer after Perlae ijectio. /6 patiets with atibodies agaist Perlae had adverse evets at the ijectio site as compared to the local adverse evet rate observed i the etire Perlae populatio (i.e., 4/5 (9%)). All the adverse evets i the patiets with a humoral respose agaist Perlae were mild i severity. Immediate type ski testig demostrated that o patiet developed IgE to Perlae. Post-exposure histopathology of ski biopsies of a implat site o each patiet demostrated that o patiet developed cell-mediated immuity to Perlae. 9 (49)

30 Desig MA-4-3: Radomized, Blided, Cotrolled Cliical Study : radomized, prospective study at 3 U.S. ceters, which compared the safety, tolerability, ad pai reductio of Restylae Lyft with Lidocaie to Perlae i 6 patiets. Patiets were radomized to Restylae Lyft with Lidocaie or Perlae treatmet i a withi-patiet model of bilateral asolabial folds (NLFs) correctio, with oe treatmet assiged to oe side ad the other treatmet to the remaiig side. Patiets ad treatig physicias were blided; evaluatig physicias were idepedet ad blided. The study icluded 5.7% of patiets with darker ski types based o classificatio of Fitzpatrick Ski Types IV, V, or VI (36.7% Ski Type IV ad 5.% Ski Type V or VI). Pai was assessed by each patiet for each treatmet site idepedetly o the Visual Aalog Scale (VAS) at the ed of ijectio ad at 5-miute itervals for 6 miutes post-treatmet. Patiet assessmet of appearace usig the Global Aesthetic Improvemet Scale (GAIS) (Very much improved / much improved / improved / o chage / worse) was performed at the Day 4 visit. Safety was studied with 4-day follow-up. Edpoits Primary: The proportio of patiets that had a withi-patiet differece i the VAS (Perlae -Restylae Lyft with Lidocaie ) of at least mm at ijectio together with a 95% cofidece iterval. The objective was to show that the cofidece iterval lay above 5%. Secodary: The proportio of patiets that had a withi-patiet differece i VAS of at least mm at post-ijectio time poits (5, 3, 45 ad 6 miutes after ijectio) together with a 95% cofidece iterval, the mea VAS by treatmet ad withi-patiet differece i VAS at each time poit, the compariso of VAS betwee Restylae Lyft with Lidocaie ad Perlae, at each time poit, ad patiet assessmet o GAIS by treatmet. Safety assessmets icluded: collectio of patiet symptoms i a 4-day diary ad ivestigator evaluatio of adverse evets at 4 days. 3 (49)

31 Outcomes Demographics: The study erolled 6 patiets with moderate to severe NLF wrikles. The patiets were predomiatly healthy ethically diverse females. Geder Female: 56 (93.3%); Male: 4 (6.7%) Ethicity White: 39 (65.%); Hispaic or Latio: 6 (6.7%); Africa America: 5 (8.3%) Fitzpatrick Ski Type- Type I-III; 9 (48.3 %); Type IV: (36.7%); Type V ad VI: 9 (5.%) Volume: The mea volume of Restylae Lyft with Lidocaie per wrikle was. ml. The mea volume of Perlae per wrikle was. ml. Volume Ijected per Wrikle (ml) (Study MA-4-3) Treatmet Restylae Lyft with Lidocaie per NLF Volume (ml) Mea Std Mi Media Max Perlae per NLF Differece withi patiet* * Perlae volume - Restylae Lyft with Lidocaie volume Abbreviatios: = umber of patiets; std = stadard deviatio; Mi = miimum; Max = maximum Primary: The primary efficacy aalysis for pai reductio showed that 95.% of patiets had a withi-patiet differece i VAS (Perlae mius Restylae Lyft with Lidocaie ) of at least mm at the time of ijectio. The primary objective was met, sice statistically more tha 5% of patiets had at least mm lower VAS score o the side treated with Restylae Lyft with Lidocaie (cofidece iterval was 86. to 99.). At 5 miutes post ijectio, 56.7% still had a withi-patiet differece i VAS of at least mm. Treatmet Differece (Δ) i VAS (Perlae Side Restylae Lyft with Lidocaie Side) ITT Populatio (Study MA-4-3) Time poit No. of patiets with assessmets** Number of patiets with Δ > mm % 95% LCL 95% UCL Treatmet* Miutes Miutes Miutes Miutes * Primary edpoit ** Deomiator (N), % = */N; UCL=upper cofidece limit; LCL=lower cofidece limit 3 (49)

32 Secodary: Both pai scores decreased over time, but the mea withi-patiet differece o VAS (Perlae Restylae Lyft with Lidocaie ) was statistically sigificatly larger tha zero at all time poits (at ijectio ad at 5, 3, 45 ad 6 miutes post-ijectio). Patiets Mea VAS Assessmets of Pai by Time Poit (Study MA-4-3) Time poit VAS pai by treatmet (mm) Restylae Lyft with Lidocaie Perlae VAS differece (mm) * p-value** Treatmet <. 5 Miutes <. 3 Miutes <. 45 Miutes <. 6 Miutes * Withi-patiet differece (Perlae side Restylae Lyft with Lidocaie side), ** Oe-sample T-test At Day 4, patiets showed improvemet from baselie: 95% o the Restylae Lyft with Lidocaie side of the face ad 96.7% o the Perlae side of the face. Global Aesthetic Improvemet Scale (GAIS) Evaluatio at the Day 4 Visit (Study MA-4-3) GAIS Category Restylae Lyft with Lidocaie Perlae % % Very Much Improved (4) Much Improved (3) Improved () No Chage () Worse ().. 3 (49)

33 No-U.S. Cliical Studies Desig Edpoits 3GE: Prospective, Radomized, Blided, Cotrolled Cliical Study : radomized, prospective study at 6 Caadia ceters, which compared the safety ad effectiveess of Perlae ad Hylaform. Patiets were radomized to either Perlae or Hylaform i a withi-patiet model of augmetatio correctio of bilateral asolabial folds (NLFs) with oe treatmet assiged to oe side ad the other treatmet to the other side. A touch-up was allowed weeks after iitial treatmet. Patiets were partially masked; evaluatig physicias were idepedet ad masked; treatig physicias were partially masked. Effectiveess was studied with 6 moths follow-up. Safety was studied with 6 moths follow-up. Effectiveess Primary: The differece i effect of Perlae as compared to Hylaform o the visual severity of the NLFs, as assessed by a Blided Evaluator at 6 moths after baselie. The primary evaluatio parameter was a five-step validated Wrikle Severity Ratig Scale (WSRS) score (abset, mild, moderate, severe, extreme) by the Blided Evaluator at 6 moths. Success was defied as maitaiig at least a oe poit improvemet of the NLF o the WSRS at 6 moths after optimal correctio was achieved. The percet of successful NLFs after Perlae ad cotrol treatmets were compared, as well as a withi-patiet matched aalysis (McNemar s Test). Secodary: Wrikle Severity Ratig Scale (WSRS) was assessed at other follow-up poits ( weeks ad 3, 4.5, ad 6 moths after optimal correctio) by the Blided Evaluator ad the patiet. Global Aesthetic Improvemet (GAI): very much improved /much improved / improved / o chage / worse, assessed at same time poits by patiet. Outcomes Safety assessmets icluded: ivestigator evaluatio of adverse evets at all time poits. Demographics: The study erolled 5 patiets with moderate to severe asolabial fold wrikles. The patiets were predomiatly healthy white females. The study was completed by 4 of 5 patiets at six moths ad additioal safety data were available i of 5 patiets at 9 moths. Geder Female: 4 (93%); Male: (7%) Ethicity White: 4/5 (95%); No-caucasia: 8/5 (5%) 33 (49)

34 Efficacy: The results of the blided evaluator assessmets are preseted i Table ad are based o a Itet-to-Treat (ITT) aalysis. At 6 moths, 3/5 (75%) of the Perlae-treated NLFs maitaied at least a sigle poit improvemet o the WSRS compared to 57/5 (38%) of the cotrol-treated NLFs. Table. Blided Evaluator Wrikle Severity Respose Rates Time poit Number of NLFs No. of Perlae NLFs maitaiig Uit Improvemet o WSRS No. of Hylaform NLFs maitaiig Uit Improvemet o WSRS 3 moths 5 3 (87%) 94 (63%) 4.5 moths 5 (73%) 69 (46%) 6 moths 5 3 (75%) 57 (38%) Table shows the results for the withi-patiet ivestigator assessmet of NLF o the WSRS. Table. Evaluatig Ivestigator s Assessmet of NLF Severity; Score Chage Mos. after last treatmet From Pre-Treatmet Util 3, 4.5, ad 6 Moths After Last Treatmet Perlae superior to Perlae equal to Hylaform superior to p-value* Hylaform Hylaform Perlae 3 95 (63.3%) 46 (3.7%) 9 (6.%) p< (58.%) 54 (36.%) 9 (6.%) p< (64.%) 4 (8.%) (8.%) p<. * McNemar s test with %=/N, where N=umber of patiets i the ITT populatio Desig 3GE: Prospective, Radomized, Blided, Cotrolled Cliical Study : radomized, prospective study at Scadiavia ceters, which compared the safety ad effectiveess of Perlae ad Zyplast. Patiets were radomized to either Perlae or Zyplast i a withi-patiet model of augmetatio correctio of bilateral asolabial folds (NLFs) with oe treatmet assiged to oe side ad the other treatmet to the other side. Patiets were partially masked; evaluatig physicias were idepedet ad masked; treatig physicias were partially masked. A touch-up was allowed weeks after the iitial treatmet. Re-treatmet was allowed at 6 or 9 moths. Effectiveess was studied with 9 moths follow-up. Safety was studied with moths follow-up. Edpoits Effectiveess Primary: Superiority of correctio of the NLF by Perlae as compared to Zyplast based o the visual severity of the NLF, as assessed by a Blided Evaluator at 6 moths after optimal correctio was achieved. The primary evaluatio parameter was a five-step validated Wrikle Severity Ratig Scale (WSRS) score (abset, mild, moderate, severe, extreme) by the Blided Evaluator at 6 moths. NLF success was defied as maitaiig at least a oe poit improvemet o the WSRS at 6 moths after optimal correctio was achieved. The withi patiet compariso of Perlae ad cotrol treatmets was evaluated i a 34 (49)

35 matched aalysis (McNemar s Test). Secodary: Superiority of correctio of the NLF by Perlae or Zyplast based o the visual severity of the NLFs, as assessed by a Blided Evaluator at 9 moths after baselie. Safety assessmets icluded: ivestigator evaluatio of adverse evets at all time poits. Outcomes Demographics: The study erolled 68 patiets with correctable NLF wrikles. The patiets were predomiatly healthy white females. Geder Female: 65 (96%); Male: 3 (4%) Ethicity White: 68/68 Efficacy: The results of the blided evaluator assessmets are preseted i Table 3. At the primary effectiveess time poit of 6 moths, the Perlae-treated NLF experieced more improvemet from baselie (judged by the WSRS) i 5% of the patiets; the cotrol-treated side experieced more improvemet i.3% of the patiets. Table 3. Evaluatig Ivestigator s Assessmet; Differece i the Severity Ratig Scale From Pre-Treatmet Util, 4, 6, ad 9 Moths After Baselie Time poit Perlae NLF is Perlae NLF Cotrol NLF is superior to cotrol is equal to superior to p-value NLF cotrol NLF Perlae NLF moths 3 (47.%) 8 (4.%) 8 (.8%). 4 moths 38 (55.9%) 5 (36.8%) 5 (7.4%). 6 moths 34 (5.%) 7 (39.7%) 7 (.3%).3 9 moths 3 (48.8%) 6 (37.%) 6 (4.9%).39. McNemar s test. Percet = /Number of patiets i the ITT populatio at Moth 6 3. Percet = /Number of patiets i the ITT populatio at Moth 9; icludes oly patiets ot re-treated (=43) 35 (49)

36 U.S. Cliical Study to support the use of Restylae Lyft with Lidocaie i cheek augmetatio ad correctio of midface cotour deficiecies. Desig Edpoits MA-4-5: Prospective, Radomized, Blided, Cotrolled Cliical Study This was a 3: radomized, prospective study at U.S. ceters, which compared the safety ad effectiveess of Restylae Lyft with Lidocaie to a o treatmet cotrol i subjects seekig cheek augmetatio. A touch-up was allowed weeks after iitial treatmet. Patiets were re-treated at Moth ad patiets origially radomized to the o treatmet group received their iitial treatmet at Moth. Blided evaluatig physicias were idepedet ad masked; treatig physicias were umasked. Safety ad Effectiveess was studied mothly through Moth ad weeks after the Moth re-treatmet/treatmet. Ijectios were performed with the supplied 9 G TW x ½ eedle. Effectiveess Primary: The proportio of respoders with at least a oe grade icrease from the baselie assessmet of the Medicis Midface Volume Scale (MMVS) for BOTH the right ad left sides of the face at Moth as assessed by the blided evaluator. The MMVS was a four poit validated scale to assesses the fulless of the midface from Fairly Full () to Substatial Loss of Fulless (4). The proportio of respoders was calculated for each treatmet group ad compared usig Fisher s Exact Tests. Secodary: MMVS assessed at other follow-up poits (, 4, 6, 8,, ad moths after optimal correctio ad, 4, ad weeks after the Moth treatmet) by the blided evaluator ad the ivestigator. Satisfactio with treatmet as assessed by the subject ad the ivestigator usig the Global Aesthetic Improvemet Scale (GAIS). Additioal assessmet of patiet satisfactio was assessed with the FACE-Q scale. The GAIS ad FACE-Q scales were ot validated at the time of the study. Safety assessmets icluded: collectio of patiet symptoms i a 4-day diary; ivestigator evaluatio of adverse evets; ad midface safety assessmets (firmess, symmetry, movemet, fuctio, sesatio, mass formatio, ad device palpability). 36 (49)

37 Outcomes Demographics: The study erolled patiets (5 Restylae Lyft with Lidocaie ad 5 o treatmet) seekig cheek augmetatio. Overall, the mea age for study subjects was 5.9 ± 7.6 years. The study icluded 6 subjects (3%) of Fitzpatrick ski types IV, V, or VI with subjects of Fitzpatrick Ski Types V (7 subjects) ad VI (4 subjects). Baselie MMVS were similar betwee the right ad left midface with a majority of subjects (6% ad 6%, respectively) havig a MMVS score of 3 (moderate loss of fulless with slight hollowig below malar promiece). Geder Female: 83 (9%); Male: 7 (9%) Ethicity White: 78 (89%); Africa America: (5%), Asia: 3 (%), America Idia/Alaska Native (<%), Other: 8 (4%) Ijectio volumes averaged 6.7 ml (iitial + touch-up at weeks; right ad left midface combied). Efficacy: The results of the blided evaluator assessmet of midface fulless (MMVS) for Restylae Lyft with Lidocaie ad o treatmet cotrol are preseted i Table 4. I the primary effectiveess assessmet at Moth, 88.7% of the Restylae Lyft with Lidocaie ad 6.% of the o treatmet cotrol patiets had at least a poit improvemet over baselie. Similar results were see for the treatig ivestigator s assessmet of MMVS. Table 4. Proportio of Respoders Measured by the Blided Evaluator s Assessmet of Midface Fulless (MMVS) at Moth Restylae Lyft Timepoit with Lidocaie No Treatmet P-Value Right ad Left Midface Combied Moth 33 (88.7%) 8 (6.%) <. Primary edpoit N = Subjects with a missig blided evaluator assessmet at Moth for a midface are imputed usig the hot deck method. Fisher s Exact Test 37 (49)

38 Figure : Proportio of Respoders Measured by the Blided Evaluator s Assessmet of Midface Fulless (MMVS) - ITT Populatio The results of the subject s satisfactio with the aesthetic improvemet i midface fulless (GAIS) for Restylae Lyft with Lidocaie ad o treatmet cotrol are preseted i Figure. Subjects were satisfied with treatmet with 98% reportig improvemet at weeks after treatmet ad satisfactio see i 73% of subjects after moths. 38 (49)

39 Figure : Right ad Left Midface Combied: Proportio of Respoders Measured by Subject s Assessmet of GAIS by Visit ITT Populatio With regard to the photographic assessmet of MMVS coducted by a Idepedet Photographic Reviewer (IPR), the betwee-group differece i the proportio of respoders from baselie for the right ad left midface combied was statistically sigificat (p<.5) i favor of Restylae Lyft with Lidocaie treatmet at all visits except the Moth visit. The proportio of respoders from baselie i the Restylae Lyft with Lidocaie group as assessed by the IPR was 8.8% at Moth, 8.% at Moth 4, 78.6% at Moth 6, 79.7% at Moth 8, 8.7% at Moth, ad 75.7% at Moth. I the o treatmet group the proportio of right ad left midface combied respoders was 69.6% at Moth, 6.% at Moth 4, 54.% at Moth 6, 63.% at Moth 8, 63.8% at Moth, ad 57.4% at Moth. 39 (49)

Caution: Federal Law restricts this device to sale by or on the order of a physician or licensed practitioner.

Caution: Federal Law restricts this device to sale by or on the order of a physician or licensed practitioner. Restylae Lyft with Lidocaie Ijectable Gel with.% Lidocaie Cautio: Federal Law restricts this device to sale by or o the order of a physicia or licesed practitioer. Descriptio Restylae Lyft with Lidocaie

More information

Injectable Gel with 0.3% Lidocaine

Injectable Gel with 0.3% Lidocaine Patiet Brochure Table of Cotets Frequetly Asked Questios 4 Safety 6 Troubleshootig 11 Admiistratio 12 Ijectable Gel with.3% Lidocaie Post Marketig Surveillace 13 Post-treatmet Checklist 14 User Assistace

More information

RADIESSE Dermal Filler for the Correction of Moderate to Severe Facial Wrinkles and Folds, Such As Nasolabial Folds

RADIESSE Dermal Filler for the Correction of Moderate to Severe Facial Wrinkles and Folds, Such As Nasolabial Folds A PATIENT S GUIDE RADIESSE Dermal Filler for the Correctio of Moderate to Severe Facial Wrikles ad Folds, Such As Nasolabial Folds Read all the iformatio before you are treated with Radiesse dermal filler.

More information

SCULPTRA Aesthetic (First Treatment Session: N = 116) Cosmoplast (First Treatment Session: N = 117) Severity of Adverse Event a Moderate n.

SCULPTRA Aesthetic (First Treatment Session: N = 116) Cosmoplast (First Treatment Session: N = 117) Severity of Adverse Event a Moderate n. SCULPTRA AESTHETIC Rx Oly (ijectable poly-l-lactic acid) The Sculptra implat package (i.e., lyophilized vials ad syrige) are provided sterile. Cautio: Federal (USA) law restricts this device to sale by

More information

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable: UM27/189/ The study listed may iclude approved ad o-approved uses, formulatios or treatmet regimes. The results reported i ay sigle study may ot reflect the overall results obtaied o studies of a product.

More information

Primary: To assess the change on the subject s quality of life between diagnosis and the first 3 months of treatment.

Primary: To assess the change on the subject s quality of life between diagnosis and the first 3 months of treatment. Study No.: AVO112760 Title: A Observatioal Study To Assess The Burde Of Illess I Prostate Cacer Patiets With Low To Moderate Risk Of Progressio Ratioale: Little data are available o the burde of illess

More information

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA RoACTEMRA for Giat Cell Arteritis WHAT YOU SHOULD KNOW ABOUT RoACTEMRA This brochure provides key iformatio to assist i the patiet s uderstadig of the beefits ad risks associated with RoACTEMRA therapy

More information

INFORMATION FOR YOU AND YOUR FAMILY. Melody Transcatheter Pulmonary Valve Therapy

INFORMATION FOR YOU AND YOUR FAMILY. Melody Transcatheter Pulmonary Valve Therapy INFORMATION FOR YOU AND YOUR FAMILY Melody Trascatheter Pulmoary Valve Therapy This booklet is provided to help you ad your loved oes lear more about Melody Trascatheter Pulmoary Valve (TPV) Therapy. Please

More information

GSK Medicine Study Number: Title: Rationale: Study Period: Objectives: Primary Secondary Indication: Study Investigators/Centers: Research Methods

GSK Medicine Study Number: Title: Rationale: Study Period: Objectives: Primary Secondary Indication: Study Investigators/Centers: Research Methods The study listed may iclude approved ad o-approved uses, formulatios or treatmet regimes. The results reported i ay sigle study may ot reflect the overall results obtaied o studies of a product. Before

More information

PATIENT INFORMATION BOOKLET. Endovascular Stent Grafts: A Treatment for Abdominal Aortic Aneurysms

PATIENT INFORMATION BOOKLET. Endovascular Stent Grafts: A Treatment for Abdominal Aortic Aneurysms PATIENT INFORMATION BOOKLET Edovascular Stet Grafts: A Treatmet for Abdomial Aortic Aeurysms TABLE OF CONTENTS Itroductio 1 Glossary 2 Abdomial Aorta 4 Abdomial Aortic Aeurysm 5 Causes 6 Symptoms 6 Treatmet

More information

INJECTABLE IMPLANT INSTRUCTIONS FOR USE

INJECTABLE IMPLANT INSTRUCTIONS FOR USE IJECTABLE IMPLAT ISTRUCTIOS FOR USE DEVICE DESCRIPTIO RADIESSE injectable implant is a sterile, non-pyrogenic, semi-solid, cohesive implant, whose principal component is synthetic calcium hydroxylapatite

More information

Quick Reference to Transthoracic Echo Screening

Quick Reference to Transthoracic Echo Screening Quick Referece to Trasthoracic Echo Screeig Idicatio: The MitraClip Clip Delivery System is idicated for the percutaeous reductio of sigificat symptomatic mitral regurgitatio (MR 3+) due to primary abormality

More information

A PATIENT S GUIDE TO PLASMA EXCHANGE

A PATIENT S GUIDE TO PLASMA EXCHANGE Some drugs may be affected by plasma exchage; ask your doctor about ay impact to drugs you are takig. It is importat to drik water ad cosume foods high i calcium, such as cheese or milk. This ca help your

More information

Information Following Treatment for Patients with Early Breast Cancer. Bradford Teaching Hospitals. NHS Foundation Trust

Information Following Treatment for Patients with Early Breast Cancer. Bradford Teaching Hospitals. NHS Foundation Trust Iformatio Followig Treatmet for Patiets with Early Breast Cacer Bradford Teachig Hospitals NHS Foudatio Trust What happes ext? You have ow completed your iitial treatmet to remove your breast cacer. There

More information

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Introduction/Background. Research Team.

Early Ambulation Reduces the Risk of Venous Thromboembolism After Total Knee Replacement. Introduction/Background. Research Team. Research Team Early Ambulatio Reduces the Risk of Veous Thromboembolism After Total Kee Replacemet Marily Szekedi, PhD, RN Baafsheh Sadeghi, MD, PhD, School of Medicie, Uiversity of Califoria Davis Patrick

More information

Mechanism of Action: The Importance of Liver THR-β in NASH

Mechanism of Action: The Importance of Liver THR-β in NASH MGL-3196, a selective thyroid hormoe receptor-beta agoist, sigificatly decreases hepatic fat i NASH patiets at 12 weeks, the primary edpoit i a 36 week serial liver biopsy study Stephe Harriso 1, Sam Moussa

More information

Simple intervention to improve detection of hepatitis B and hepatitis C in general practice

Simple intervention to improve detection of hepatitis B and hepatitis C in general practice Simple itervetio to improve detectio of hepatitis B ad hepatitis C i geeral practice Zayab al-lami (GP-Birmigham) Co-authors:-Sarah Powell, Sally Bradshaw, Amada Lambert, David Mutimer ad Adrew Rouse Presetatio

More information

Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials

Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials Drug Saf (2018) 41:429 440 https://doi.org/10.1007/s40264-017-0623-1 ORIGINAL RESEARCH ARTICLE Cardiovascular Profile of : Aalysis of Pooled Data from Three Radomized, Double-Blid, -Cotrolled Trials Dao

More information

Meningococcal B Prevention Tools for Your Practice

Meningococcal B Prevention Tools for Your Practice Meigococcal B Prevetio Tools for Your Practice NAPNAP MeB Facts for HCPs Fast Facts Although ucommo, MeB is potetially fatal. 1 MeB symptoms progress quickly; death ca occur i 24 hours or less. MeB accouts

More information

Reporting Checklist for Nature Neuroscience

Reporting Checklist for Nature Neuroscience Correspodig Author: Mauscript Number: Mauscript Type: Galea NNA48318C Article Reportig Checklist for Nature Neurosciece # Figures: 4 # Supplemetary Figures: 2 # Supplemetary Tables: 1 # Supplemetary Videos:

More information

Whether you have a bacterial infection or a viral infection, there are things you can do to help yourself feel better:

Whether you have a bacterial infection or a viral infection, there are things you can do to help yourself feel better: HEALTHPLUS, AN AMERIGROUP COMPANY MakeHealth Happe Vol. 2, 2013 Do I Need Atibiotics? Atibiotics are medicies used to treat bacterial ifectios ad keep them from spreadig. But if a virus makes you sick,

More information

YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2

YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2 YOUR BEST DAYS START WITH BETTER PROTECTION FROM LOWS. *,1,2 Oly SmartGuard TM from MiiMed takes actio for you whe you eed it most. MiiMed 530G system HIT THE ROAD. WORRY LESS ABOUT GOING LOW. *,1,3 37.5%

More information

Retention in HIV care among a commercially insured population,

Retention in HIV care among a commercially insured population, Retetio i HIV care amog a commercially isured populatio, 2006-2012 Kathy Byrd, MD, MPH 10th Iteratioal Coferece o HIV Treatmet ad Prevetio Adherece Jue 28 30, 2015 Natioal Ceter for HIV/AIDS, Viral Hepatitis,

More information

Modified Early Warning Score Effect in the ICU Patient Population

Modified Early Warning Score Effect in the ICU Patient Population Lehigh Valley Health Network LVHN Scholarly Works Patiet Care Services / Nursig Modified Early Warig Score Effect i the ICU Patiet Populatio Ae Rabert RN, DHA, CCRN, NE-BC Lehigh Valley Health Network,

More information

Hospital Measures. Region 1

Hospital Measures. Region 1 Regio 1 Hospital Measures Northwest ad West Cetral: Becker, Beltrami, Clay, Clearwater, Douglas, Grat, Hubbard, Kittso, Lake of the Woods, Mahome, Marshall, Norma, Otter Tail, Peigto, Polk, Pope, Red Lake,

More information

1 Barnes D and Lombardo C (2006) A Profile of Older People s Mental Health Services: Report of Service Mapping 2006, Durham University.

1 Barnes D and Lombardo C (2006) A Profile of Older People s Mental Health Services: Report of Service Mapping 2006, Durham University. The Natioal Audit Office udertook a self-assessmet cesus of Commuity Metal Health Teams for Older People (CMHTs) betwee September ad December 2006. The overall fidigs are preseted i the Natioal Audit Office

More information

Systemic and Novel Management of Alopecia Areata in Children. Alopecia Areata: Prognosis. Alopecia Areata. Alopecia Areata: Pathogenesis

Systemic and Novel Management of Alopecia Areata in Children. Alopecia Areata: Prognosis. Alopecia Areata. Alopecia Areata: Pathogenesis Systemic ad Novel Maagemet of Alopecia Areata i Childre Kimberly Morel, MD, FAAD, FAAP Associate Professor of Dermatology & Pediatrics S006 - Treatig Severe Ski Disease i Childre 02/16/2018, 9:00 AM Room

More information

Certify your stroke care program. Tell your community you re ready when needed.

Certify your stroke care program. Tell your community you re ready when needed. Certify your stroke care program. Tell your commuity you re ready whe eeded. Stroke Certificatio Optios STROKE READY PRIMARY STROKE Stroke Ready Certificatio Demostrates to commuity emergecy services ad

More information

Opinion 22 January 2014

Opinion 22 January 2014 The legally bidig text is the origial Frech versio TRANSPARENCY COMMITTEE Opiio 22 Jauary 214 VELCADE 1 mg, powder for solutio for ijectio B/1 vial (CIP: 349 386 657 9 6) VELCADE 3.5 mg, powder for solutio

More information

DESCRIPTION 1. Composition

DESCRIPTION 1. Composition Shioogi & Co., Ltd. 1 Revised: Jue 2009 (8th versio) Stadard Commodity Classificatio No. of Japa 876133 - Oxacephem atibiotic aget - SHIOMARIN for Itraveous Ijectio 1 g < Latamoxef sodium for ijectio >

More information

Hospital Measures. Region 3. Twin Cities Metro: Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, Washington

Hospital Measures. Region 3. Twin Cities Metro: Anoka, Carver, Dakota, Hennepin, Ramsey, Scott, Washington Regio 3 Hospital Measures Twi Cities Metro: Aoka, Carver, Dakota, Heepi, Ramsey, Scott, Washigto 48 Hospital Measures November 2010 2010 Health Care Quality Report Hospital Measures Quality of Care for

More information

What are minimal important changes for asthma measures in a clinical trial?

What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999; 14: 23±27 Prited i UK ± all rights reserved Copyright #ERS Jourals Ltd 1999 Europea Respiratory Joural ISSN 0903-1936 What are miimal importat chages for asthma measures i a cliical

More information

2017 Oregon Dental Conference Course Handout

2017 Oregon Dental Conference Course Handout 2017 Orego Detal Coferece Course Hadout Jim Kratochvil, DDS Course 8118: Cliical Approach to the Diagosis of Oral Lesios Thursday, April 6 10:30 am - 12 pm Cliical Approach to Diagosis of Oral Lesios Jim

More information

Intrathecal pumps for pain therapy. Lennart Stieglitz

Intrathecal pumps for pain therapy. Lennart Stieglitz Itrathecal pumps for pai therapy Leart Stieglitz Itrathecal pumps itrathecal? History Morphi Baclofe Evaluatio Implatatio Complicatios Itrathekale Schmerztherapie Pai is perfect miserie, the worst of evils,

More information

prescription drug Approval No. solution Attached dissolving (Content per kit) Flomoxef sodium 1 g (potency) Sodium chloride 50 mg

prescription drug Approval No. solution Attached dissolving (Content per kit) Flomoxef sodium 1 g (potency) Sodium chloride 50 mg Shioogi & Co., Ltd. Revised: Jue 9 (9th versio) Stadard Commodity Classificatio o. of Japa 87 - Oxacephem atibiotic aget - FLUMARI for Itraveous Ijectio. g FLUMARI for Itraveous Ijectio g FLUMARI Kit for

More information

Clinical Research The details of the studies undertaken year wise along with the outcomes is given below: SNo Name of Project

Clinical Research The details of the studies undertaken year wise along with the outcomes is given below: SNo Name of Project No. studies take Cliical Research 2012-13 No. publi 9 4 The details the studies take year wise alog with the outcomes is give below: 1. Homoeopathic therapy for lower uriary tract symptoms i me with Beig

More information

Patient Enrollment Form

Patient Enrollment Form Patiet Erollmet Form 1 HEALTHCARE PROFESSIONAL (HCP) HCP Name Facility Name Address 2489 W. BUSINESS 77 City SAN BENITO State TXZip 78586 Tel ( 956 ) 412-2700 Fax ( 956 ) 361-4742 HCP Email KATHLEEN SALVATORE

More information

More than skin deep. The medical uses of BOTOX

More than skin deep. The medical uses of BOTOX The medical uses of More tha ski deep Idicatios is a prescriptio medicie that is ijected ito muscles ad used: to treat the abormal head positio ad eck pai that happes with cervical dystoia (CD) i people

More information

Basic Requirements. of meeting cow herd production and profitability goals for the beef cattle enterprise.

Basic Requirements. of meeting cow herd production and profitability goals for the beef cattle enterprise. Basic Requiremets It is imperative that cattle producers have a adequate uderstadig of the basic utriet requiremets of the cow herd to make iformed ad effective utritio-related decisios. by Matt Hersom,

More information

DEMAND RESULTS. TRUST ENDURANT.

DEMAND RESULTS. TRUST ENDURANT. DEMAND RESULTS. TRUST ENDURANT. Edurat ll AAA Stet System Edurat IIs AAA Stet System THE ENDURANT II SYSTEM FAMILY OF PRODUCTS Icludes Edurat II, Edurat II AUI ad Edurat IIs stets. Desiged to meet a wide

More information

Valve Aortic Accessories Trifecta Valve Sizer Set Handles Global Headquarters Cardiovascular Division St. Jude Medical Coordination Center BVBA

Valve Aortic Accessories Trifecta Valve Sizer Set Handles Global Headquarters Cardiovascular Division St. Jude Medical Coordination Center BVBA Trifecta Valve Whe the Goal Is Superior Hemodyamics 1 The Valve Is Trifecta. Itroducig the ext-geeratio pericardial tissue heart valve ad perfect complemet to the lie of tissue valves from St. Jude Medical

More information

M e sotheliom a. a UK nursing and inform ation project. Mavis Robinson Project Manager

M e sotheliom a. a UK nursing and inform ation project. Mavis Robinson Project Manager M e sotheliom a a UK ursig ad iform atio project Mavis Robiso Project Maager Mesotheliom a Mesothelioma is a cacer. It most commoly affects the outer liig of the lugs (the pleura). I over 70% of cases

More information

There s. more. to you THAT S WHY THERE S MORE TO GAMUNEX-C. *CIDP=Chronic inflammatory demyelinating polyneuropathy.

There s. more. to you THAT S WHY THERE S MORE TO GAMUNEX-C. *CIDP=Chronic inflammatory demyelinating polyneuropathy. There s more to you THAT S WHY THERE S MORE TO GAMUNEX-C YOUR GUIDE TO UNDERSTANDING THE TREATMENT OF CIDP * *CIDP=Chroic iflammatory demyeliatig polyeuropathy. Please see Importat Safety Iformatio o pages

More information

Stroke in the emergency department

Stroke in the emergency department Cambridge Uiversity Press 978-0-521-67494-2 - Acute Stroke Care: A Maual from the Uiversity of Texas-Housto Stroke Team Ke Uchio, Jeifer K. Pary ad James C. Grotta More iformatio 1 Stroke i the emergecy

More information

Plantar Pressure Difference: Decision Criteria of Motor Relearning Feedback Insole for Hemiplegic Patients

Plantar Pressure Difference: Decision Criteria of Motor Relearning Feedback Insole for Hemiplegic Patients 22 4th Iteratioal Coferece o Bioiformatics ad Biomedical Techology IPCBEE vol.29 (22) (22) IACSIT Press, Sigapore Platar Pressure Differece: Decisio Criteria of Motor Relearig Feedback Isole for Hemiplegic

More information

Psychophysiological Alterations in Posttraumatic Stress Disorder

Psychophysiological Alterations in Posttraumatic Stress Disorder Psychophysiological Alteratios i Posttraumatic Stress Disorder Developmet Over Time ad Respose to Treatmet Michael G. Griffi, Ph.D. This work was supported by NIMH grats MH55688 (Griffi) ad MH55542 (Resick)

More information

Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus

Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus Cliical evidece of the role of belimumab i the treatmet of systemic lupus erythematosus Cli. Ivest. (2011) 1(11), 1555 1561 Belimumab is a huma moocloal atibody that bids soluble B lymphocyte stimulator,

More information

Objectives. Sampling Distributions. Overview. Learning Objectives. Statistical Inference. Distribution of Sample Mean. Central Limit Theorem

Objectives. Sampling Distributions. Overview. Learning Objectives. Statistical Inference. Distribution of Sample Mean. Central Limit Theorem Objectives Samplig Distributios Cetral Limit Theorem Ivestigate the variability i sample statistics from sample to sample Fid measures of cetral tedecy for distributio of sample statistics Fid measures

More information

Sexuality and chronic kidney disease

Sexuality and chronic kidney disease Sexuality ad chroic kidey disease T H E K I D N E Y F O U N D A T I O N O F C A N A D A 1 Sexuality ad chroic kidey disease Let s talk about it Sexuality is a vital part of us all. It icludes may aspects

More information

Skeletal System. Bones Protect. Bones. Bones Store. Bones Move SECTION 2: THE SKELETAL SYSTEM 4/4/16

Skeletal System. Bones Protect. Bones. Bones Store. Bones Move SECTION 2: THE SKELETAL SYSTEM 4/4/16 Skeletal System Skeletal system: the orga system whose primary fuctio is to support ad protect the body ad to allow the body to move SECTION 2: THE SKELETAL SYSTEM Boes The adult huma skeleto has 206 boes.

More information

Click to Edit Master Title

Click to Edit Master Title Click to Edit Master Title Persoalized Pai Recovery for City & Couty of Sa Fracisco Employees & Retirees March 9, 2017 Click to Edit Master Title Retirees Police Teachers DPW Desk Fire Fighters PUC MTA

More information

Review for Chapter 9

Review for Chapter 9 Review for Chapter 9 1. For which of the followig ca you use a ormal approximatio? a) = 100, p =.02 b) = 60, p =.4 c) = 20, p =.6 d) = 15, p = 2/3 e) = 10, p =.7 2. What is the probability of a sample

More information

LESSON PLAN. SUBJECT : COMMUNITY PHYSIOTHERAPY AND REHABILITATION Class : IV BPT VII Semester (2018) Class Incharge : Dr.

LESSON PLAN. SUBJECT : COMMUNITY PHYSIOTHERAPY AND REHABILITATION Class : IV BPT VII Semester (2018) Class Incharge : Dr. Dr. D.Y. PATIL COLLEGE OF PHYSIOTHERAPY Dr. D.Y.PATIL VIDYAPEETH, PUNE (Deemed to be Uiversity) Re-accredited by NAAC with a CGPA of 3.62 o a four poit scale at 'A' Grade. (A ISO 9001:2008 Certified Uiversity)

More information

Measures of Spread: Standard Deviation

Measures of Spread: Standard Deviation Measures of Spread: Stadard Deviatio So far i our study of umerical measures used to describe data sets, we have focused o the mea ad the media. These measures of ceter tell us the most typical value of

More information

Hypertension in patients with diabetes is a well recognized

Hypertension in patients with diabetes is a well recognized Cotrol of Hypertesio amog Type II Diabetics Kawther El-Shafie, Sayed Rizvi Abstract Objectives: Numerous studies have cofirmed the high prevalece of hypertesio amog type 2 diabetics, ad that itesive hypertesive

More information

There s. to them THAT S WHY THERE S MORE TO GAMUNEX-C

There s. to them THAT S WHY THERE S MORE TO GAMUNEX-C There s more to them THAT S WHY THERE S MORE TO GAMUNEX-C YOUR GUIDE TO CARING FOR SOMEONE WITH CIDP* *Chroic iflammatory demyeliatig polyeuropathy. TABLE OF CONTENTS What is CIDP?... 4 What causes CIDP?...

More information

MICHELANGELO: OASIS 5 Women s Substudy

MICHELANGELO: OASIS 5 Women s Substudy MICHELANGELO: OASIS 5 Wome s Substudy Dr. Eva Swah Departmet of Cardiology, Heart Cetre, Uiversity Hospital, Liköpig Swede Disclosure Fuded by Saofi-Sythelabo, Orgao NV ad GSK Dr. Swah has o coflicts of

More information

The relationship between hypercholesterolemia as a risk factor for stroke and blood viscosity measured using Digital Microcapillary

The relationship between hypercholesterolemia as a risk factor for stroke and blood viscosity measured using Digital Microcapillary Joural of Physics: Coferece Series PAPER OPEN ACCESS The relatioship betwee hypercholesterolemia as a risk factor for stroke ad blood viscosity measured usig Digital Microcapillary To cite this article:

More information

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods:

GSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: The study listed may iclude approved ad o-approved uses, mulatios or treatmet regimes. The results reported i ay sigle study may ot reflect the overall results obtaied o studies of a product. Bee prescribig

More information

talking about Men s Health...

talking about Men s Health... Usdaw talkig about Me s Health... Male Cacers This leaflet is desiged to raise me s awareess of the importace of maitaiig their health, particularly whe it comes to cacer. It highlights the two most commo

More information

REVANESSE VERSA PROFESSIONAL DIRECTIONS FOR USE

REVANESSE VERSA PROFESSIONAL DIRECTIONS FOR USE REVANESSE VERSA PROFESSIONAL DIRECTIONS FOR USE Caution: Federal Law restricts this device to sale by, or on the order of, a physician or properly licensed practitioner. DESCRIPTION Revanesse Versa should

More information

SPONDYLODISCITIS KEY POINTS

SPONDYLODISCITIS KEY POINTS KEY POINTS SEPPO KOSKINEN, M.D., Ph.D. Professor Divisio of Radiology Departmet of Cliical Sciece, Itervetio ad Techology (CLINTEC) Seior Cosultat Fuctio Imagig & Physiology Fuctioal Area for Trauma ad

More information

New guidance from the Royal College of Radiologists Standards for Intravascular Contrast administration to adult patients 9, 11, 12

New guidance from the Royal College of Radiologists Standards for Intravascular Contrast administration to adult patients 9, 11, 12 Admiistratio of Itraveous (IV) Iodiated Cotrast Media (CM) i the Radiology Departmet Type: Cliical Guidelies Register No: 16031 Status: Public Developed i respose to: Cotributes to CQC Core Stadard umber:

More information

A guide to immunisations up to 13 months of age

A guide to immunisations up to 13 months of age A guide to immuisatios up to 13 moths of age The complete routie childhood immuisatio programme These booklets describe the immuisatios offered to your child durig the first 18 years of their life. A guide

More information

Appendix 1 (19) Appendix 1 Tables of included studies. Surgery to treat gallstones and acute inflammation of the gallbladder Report 259 (2016)

Appendix 1 (19) Appendix 1 Tables of included studies. Surgery to treat gallstones and acute inflammation of the gallbladder Report 259 (2016) Appedix 1 (19) Surgery to treat gallstoes ad acute iflammatio of the gallbladder Report 259 (2016) Appedix 1 Tables of icluded studies SBU States beredig för medicisk och social utvärderig www.sbu.se Telefo

More information

Chem 135: First Midterm

Chem 135: First Midterm Chem 135: First Midterm September 30 th, 2013 Please provide all aswers i the spaces provided. You are ot allowed to use a calculator for this exam, but you may use (previously disassembled) molecular

More information

The Human Body. Introduction. Human body. Nervous system Musculoskeletal system. Cardiovascular system. Produces movements.

The Human Body. Introduction. Human body. Nervous system Musculoskeletal system. Cardiovascular system. Produces movements. Itroductio Huma body Nervous system Musculoskeletal system Muscular forces Muscle extesio ad cotractio Complex system of muscles ad boes Produces movemets Cardiovascular system Heart Blood vessels Respiratory

More information

Hospital Measures. Region 2

Hospital Measures. Region 2 Regio 2 Hospital Measures Northeast ad Cetral: Aitki, Beto, Carlto, Cass, Chisago, Cook, Crow Wig, Isati, Itasca, Kaabec, Koochichig, Lake, Mille Lacs, Morriso, Pie, Sherbure, St. Louis, Stears, Todd,

More information

Comparison of speed and accuracy between manual and computer-aided measurements of dental arch and jaw arch lengths in study model casts

Comparison of speed and accuracy between manual and computer-aided measurements of dental arch and jaw arch lengths in study model casts Compariso of speed ad accuracy betwee maual ad computeraided measuremets (Diah Wibisoo, et.al.) Compariso of speed ad accuracy betwee maual ad computeraided measuremets of detal arch ad jaw arch legths

More information

DISTRIBUTION AND PROPERTIES OF SPERMATOZOA IN DIFFERENT FRACTIONS OF SPLIT EJACULATES*

DISTRIBUTION AND PROPERTIES OF SPERMATOZOA IN DIFFERENT FRACTIONS OF SPLIT EJACULATES* FERTILITY AND STERILITY Copyright 1972 by The Williams & Wilkis Co. Vol. 23, No.4, April 1972 Prited i U.S.A. DISTRIBUTION AND PROPERTIES OF SPERMATOZOA IN DIFFERENT FRACTIONS OF SPLIT EJACULATES* R. ELIASSON,

More information

One-week Oral Challenge with Penicillin in Diagnosis of Penicillin Allergy

One-week Oral Challenge with Penicillin in Diagnosis of Penicillin Allergy Acta Derm Veereol 2012; 92: 307 312 INVESTIGATIVE REPORT Oe-week Oral Challege with Peicilli i Diagosis of Peicilli Allergy Jai Hjortlud, Charlotte Gotthard Mortz, Per Stahl Skov, Esbe Eller, Joha Millig

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud Uiversity Nijmege The followig full text is a publisher's versio. For additioal iformatio about this publicatio click this lik. http://hdl.hadle.et/066/5655

More information

Total patients reporting symptoms n (%)

Total patients reporting symptoms n (%) Printer-Friendly Version* Caution: Federal Law restricts this device to sale by or on the order of a physician or licensed practitioner. Description is a gel of hyaluronic acid generated by Streptococcus

More information

Statistical Analysis and Graphing

Statistical Analysis and Graphing BIOL 202 LAB 4 Statistical Aalysis ad Graphig Aalyzig data objectively to determie if sets of data differ ad the to preset data to a audiece succictly ad clearly is a major focus of sciece. We eed a way

More information

Pilot and Exploratory Project Support Grant

Pilot and Exploratory Project Support Grant KEY DATES LETTERS OF INTENT DUE November 3, 2014 5:00 pm est FULL PROPOSAL INVITATIONS November 17, 2014 FULL PROPOSAL DEADLINE Jauary 15, 2015 5:00 pm est NOTIFICATION OF AWARDS April, 2015 Pilot ad Exploratory

More information

Impression taking for fix appliences, sectional models

Impression taking for fix appliences, sectional models Impressio takig for fix applieces, sectioal models Dr. Judit Borbély 2018 2 2 Impressio soft, semifluid material placed i the mouth ad allowig that material to set 1. It should be a exact duplicatio

More information

Sampling Distributions and Confidence Intervals

Sampling Distributions and Confidence Intervals 1 6 Samplig Distributios ad Cofidece Itervals Iferetial statistics to make coclusios about a large set of data called the populatio, based o a subset of the data, called the sample. 6.1 Samplig Distributios

More information

APPROVAL REQUIRED. By approving this proof you are confirming that the contact information is correct.

APPROVAL REQUIRED. By approving this proof you are confirming that the contact information is correct. APPROVAL REQUIRED Attached is a proof for your review. Please pay particular attetio to cotact iformatio such as phoe umbers, email addresses, web addresses ad mailig address. By approvig this proof you

More information

Ovarian Cancer Survival

Ovarian Cancer Survival Dairy Products, Calcium, Vitami D, Lactose ad Ovaria Cacer: Results from a Pooled Aalysis of Cohort Studies Stephaie Smith-Warer, PhD Departmets of Nutritio & Epidemiology Harvard School of Public Health

More information

The game of football has been played competitively at

The game of football has been played competitively at Joural of Athletic Traiig 2007;42(2):221 233 by the Natioal Athletic Traiers Associatio, Ic www.jouralofathletictraiig.org Descriptive Epidemiology of Collegiate Me s Football Ijuries: Natioal Collegiate

More information

CHAPTER 8 ANSWERS. Copyright 2012 Pearson Education, Inc. Publishing as Addison-Wesley

CHAPTER 8 ANSWERS. Copyright 2012 Pearson Education, Inc. Publishing as Addison-Wesley CHAPTER 8 ANSWERS Sectio 8.1 Statistical Literacy ad Critical Thikig 1 The distributio of radomly selected digits from to 9 is uiform. The distributio of sample meas of 5 such digits is approximately ormal.

More information

Raising Healthy Kids: Colostrum Management and Prevention of Failure of Passive Transfer

Raising Healthy Kids: Colostrum Management and Prevention of Failure of Passive Transfer 11/11/14! Raisig Healthy Kids: Colostrum Maagemet ad Prevetio of Failure of Passive Trasfer Cassi Plummer, DVM Iowa State Uiversity College of Veteriary Medicie Itroductio Colostrum Maagemet Failure of

More information

Methodology National Sports Survey SUMMARY

Methodology National Sports Survey SUMMARY Methodology 017 Natioal Sports Survey Prepared by Priceto Survey Research Associates Iteratioal for the Washigto Post ad the Uiversity of Massachusetts Lowell August 017 SUMMARY The 017 Natioal Sports

More information

Estimation and Confidence Intervals

Estimation and Confidence Intervals Estimatio ad Cofidece Itervals Chapter 9 McGraw-Hill/Irwi Copyright 2010 by The McGraw-Hill Compaies, Ic. All rights reserved. GOALS 1. Defie a poit estimate. 2. Defie level of cofidece. 3. Costruct a

More information

Safety concerns regarding inhaled adrenergic. Long-acting b-agonists: a review of formoterol safety data from asthma clinical trials

Safety concerns regarding inhaled adrenergic. Long-acting b-agonists: a review of formoterol safety data from asthma clinical trials Eur Respir J 2009; 33: 21 32 DOI: 10.1183/09031936.00145006 CopyrightßERS Jourals Ltd 2009 Log-actig b-agoists: a review of formoterol safety data from asthma cliical trials M.R. Sears*,#, A. Ottosso ",

More information

Management of Preschool Recurrent Wheezing and Asthma: A Phenotype-Based Approach

Management of Preschool Recurrent Wheezing and Asthma: A Phenotype-Based Approach Maagemet of Preschool Recurret Wheezig ad Asthma: A Pheotype-Based Approach Leoard B. Bacharier, MD Robert C. Struk Edowed Chair for Lug ad Respiratory Research Professor of Pediatrics & Medicie Cliical

More information

Postoperative pulmonary complications contribute importantly

Postoperative pulmonary complications contribute importantly Aals of Iteral Medicie Cliical Guidelies Preoperative Pulmoary Risk Stratificatio for Nocardiothoracic Surgery: Systematic Review for the America College of Physicias Gerald W. Smetaa, MD; Valerie A. Lawrece,

More information

Autism Awareness Education. April 2018

Autism Awareness Education. April 2018 Autism Awareess Educatio April 2018 What is Autism Autism is a wide-spectrum metal disorder that is talked about every day i health circles, but few really kow all the facts about it. Research cotiues

More information

Guide to common medical conditions

Guide to common medical conditions Guide to commo medical coditios Helpig you uderstad our uderwritig approach to the most commoly disclosed medical coditios Cacer Hypertesio Kidey stoes Metal health Sleep Apoea AMP Life Limited ABN 84

More information

Effects of Reflexotherapy on Acute Postoperative Pain and Anxiety Among Patients With Digestive Cancer

Effects of Reflexotherapy on Acute Postoperative Pain and Anxiety Among Patients With Digestive Cancer Copyright B 2008 Wolters Kluwer Health Lippicott Williams & Wilkis Shiow-Lua Tsay, PhD, RN Hsiao-Lig Che, MS, RN Su-Chiu Che, MS, RN Hug-Ru Li, PhD, RN Kua-Chia Li, PhD Effects of Reflexotherapy o Acute

More information

Depression among Patients Attending Physiotherapy Clinics in Erbil City

Depression among Patients Attending Physiotherapy Clinics in Erbil City amog Patiets Attedig.. Zaco J. Med. Sci., Vol. 13, No. (2), 2009 amog Patiets Attedig Physiotherapy Cliics i Erbil City Dr. Sirwa K. Ali * Dr. Jwa M. Zagaa ** Dr. Diyar H. Tahir *** ABSTRACT Backgroud

More information

Repeatability of the Glaucoma Hemifield Test in Automated Perimetry

Repeatability of the Glaucoma Hemifield Test in Automated Perimetry Repeatability of the Glaucoma Hemifield Test i Automated Perimetry Joae Katz,*-\ Harry A. Quigley,^ ad Alfred SommerX Purpose. To examie the cocordace of the Glaucoma Hemifield Test ad other global visual

More information

ACE-27 with Dr. Piccirillo from Washington University St. Louis. August 18, 2009

ACE-27 with Dr. Piccirillo from Washington University St. Louis. August 18, 2009 ACE-27 with Dr. Piccirillo from Washigto Uiversity St. Louis August 18, 2009 Itroductio Patiets with cacer ofte have other diseases, illesses, or coditios i additio to their idex cacer These other coditios

More information

Surgery for Congenital Heart Disease. A novel adhesion barrier facilitates reoperations in complex congenital cardiac surgery

Surgery for Congenital Heart Disease. A novel adhesion barrier facilitates reoperations in complex congenital cardiac surgery Surgery for Cogeital Heart Disease A ovel adhesio barrier facilitates reoperatios i complex cogeital cardiac surgery Thomas Walther, MD, PhD Ardawa Rasta, MD Igo Dähert, MD Volkmar Falk, MD, PhD Stefa

More information

Epilepsy and Family Dynamics

Epilepsy and Family Dynamics Epilepsy ad Family Dyamics BC Epilepsy Society November 15, 2010 Guests: Susa Murphy, Registered Nurse, Paret Rita Marchildo, Child Life Specialist, Paret Speakers: Audrey Ho PhD., R.Psych Josef Zaide

More information

IMAGING THE BIOLOGICAL EFFECT OF DOSE IN THE LIVER NORMAL TISSUE

IMAGING THE BIOLOGICAL EFFECT OF DOSE IN THE LIVER NORMAL TISSUE 8/5/2 IMAGING THE BIOLOGICAL EFFECT OF DOSE IN THE LIVER NORMAL TISSUE Yue Cao, Ph.D. Departmets of Radiatio Ocology ad Radiology Uiversity of Michiga Ackowledgemets James Balter, Ph.D. Edgar Be-Josef,

More information

Esteemed Faculty. Michael A. LeNoir MD, FAAP, FAAAI. Jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Not One More Life, Inc.

Esteemed Faculty. Michael A. LeNoir MD, FAAP, FAAAI. Jointly sponsored by AKH Inc., Advancing Knowledge in Healthcare and Not One More Life, Inc. Esteemed Faculty Michael A. LeNoir MD, FAAP, FAAAI Joitly sposored by AKH Ic., Advacig Kowledge i Healthcare ad Not Oe More Life, Ic. otoemorelife.org Allergy ad Asthma I Childre 70% o the post-test. A

More information

Table of Contents. Injectable Gel with 0.3% Lidocaine

Table of Contents. Injectable Gel with 0.3% Lidocaine Patient Brochure Table of Contents About Restylane-L 4 Safety 6 Post-Marketing Surveillance 9 About the Procedure 10 Troubleshooting 11 Injectable Gel with 0.3% Lidocaine 2 3 About Restylane-L Q What is

More information

Item Reduction and Psychometric Validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS)vhe_

Item Reduction and Psychometric Validation of the Oily Skin Self Assessment Scale (OSSAS) and the Oily Skin Impact Scale (OSIS)vhe_ Volume 12 Number 5 2009 VALUE IN HEALTH Item Reductio ad Psychometric Validatio of the Oily Ski Self Assessmet Scale (OSSAS) ad the Oily Ski Impact Scale (OSIS)vhe_504 828..837 Robert Arbuckle, MA, 1 Marci

More information